

REVIEW

Spatiotemporal Trends in the Prevalence of Obstructive Sleep Apnoea Across China: A Multilevel Meta-Analysis Incorporating Geographic and Demographic Stratification (2000-2024)

Yuqi Niu, Shanwen Sun 🝺, Yali Wang, Linlin Chen, Yefan Shao, Xiaochun Zhang

Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China

Correspondence: Xiaochun Zhang, The First Affiliated Hospital of China Medical University, 155 North Nanjing Street, Heping District, Shenyang, Liaoning, People's Republic of China, Tel +86 13898824248, Email xczhang73@cmu.edu.cn

Purpose: China bears the highest global burden of obstructive sleep apnea (OSA), yet its spatiotemporal and occupational patterns remain unclear. We quantified OSA prevalence across Chinese subpopulations, focusing on geographic disparities, temporal trends, and occupational risks.

Methods: Following PRISMA guidelines, we systematically searched six databases (2000–2024) for population-based OSA studies using polysomnography or validated portable monitoring. Two researchers independently screened studies with third-party adjudication of discrepancies. Risk of bias was assessed using Joanna Briggs Institute criteria. Random-effects models pooled prevalence estimates; meta-regression identified heterogeneity contributors. OSA diagnosis followed 2012 AASM criteria (AHI \geq 5; pediatric studies: OAHI \geq 1.5).

Results: From 62 studies (N=178,049), pooled OSA prevalence was 11.8% (95% CI:10.1–13.4%), rising from 8.1% (2000–2005) to 26.9% (2021–2024). Prevalence was higher in males vs females (11.1% vs 6.0%, P<0.001), with marked geographic disparities: Northwest China had the highest prevalence (17.8%, 16.3–19.3%) versus Southwest (6.9%, 3.7–10.9%). Drivers exhibited the highest occupational risk (15.3%). Low-quality studies overestimated prevalence (15.0% vs 7.6–10.2% in higher-quality studies), and two-step sampling yielded higher estimates than single-risk-group designs (13.6% vs 7.4%, P<0.001). Meta-regression identified survey period (β =0.036, P=0.025), male sex (β =–0.062, P=0.047), geographic area (β =0.268, P=0.035), occupation (β =0.254, P=0.047), and sampling strategy (β =–0.029, P=0.012) as key predictors of heterogeneity.

Conclusion: OSA prevalence in China has accelerated significantly. Standardized screening is urgently needed for aging populations, high-risk occupations (particularly drivers), and underserved regions. Policy priorities should address rural diagnostic inequities and integrate OSA surveillance into public health programs. Methodological harmonization is critical for tracking OSA's evolving burden. **Keywords:** obstructive sleep apnoea, OSA, prevalence, China, subgroup analysis, meta-analysis

Introduction

Obstructive sleep apnoea (OSA) is a significant chronic disorder characterized by upper airway obstruction during sleep. It presents as nocturnal apnoea and recurrent hypoventilation events. The disorder has a markedly detrimental impact on the quality of sleep and daytime functionality of patients, and is Lregarded as aL significant risk factor for cardiovascular disease, metabolic syndrome, and other health complications.^{1,2} Furthermore, it is a principal contributory factor in road traffic accidents and workplace accidents, resulting in a substantial economic burden on society.³ In recent years, there has been a notable increase in the incidence of OSA globally, with an increasing number of adults and children affected, often without timely diagnosis and treatment.⁴

879

A global epidemiological study on the prevalence of obstructive sleep apnoea (OSA) conducted in 16 countries revealed that 936 million adults aged 30-69 years had OSA, with 425 million exhibiting moderate-to-severe OSA.⁴ The highest prevalence was observed in China, followed by the United States, Brazil, and India. A review of the Asian literature in 2019 by Mirrakhimov et al identified a range of adult OSA prevalence estimates, from 3% to 97%. A subsequent review of the European literature demonstrated that the prevalence of OSA in the general adult population ranged from 9% to 38%.⁵ The Asian study reported an 11% prevalence of obstructive sleep appoea in India.⁶ The considerable disparity in these findings is attributable to a number of factors, including the diverse geographic regions under consideration, the varying study designs and methodologies employed, and the differing characteristics of the populations under investigation. It is also noteworthy that studies on OSA in the pediatric population are becoming increasingly prevalent. A number of studies have demonstrated a significant association between the prevalence of OSA in children and a range of factors, including age, sex, and obesity.⁷ A systematic evaluation of the literature revealed that the prevalence of OSA was significantly higher in obese children, reaching 22%.⁸ The available evidence from studies conducted in both developed and developing countries indicates that there are significant differences in the observed trends. In developed countries, there is a tendency for higher rates of identification and diagnosis, whereas in developing countries, the lack of relevant medical resources and awareness often results in a failure to complete a comprehensive assessment.⁴

As China transitions into the role of the world's largest developing country, the concomitant rapid economic growth and lifestyle changes are contributing to an increase in the prevalence of obstructive sleep apnea (OSA).⁹ The rapid pace of urbanization, coupled with shifts in dietary habits and evolving lifestyles, has further compounded the complexity of this health issue. Furthermore, in conjunction with the aging of the population, the prevalence of OSA is gradually increasing across different age groups. However, due to the vast geographic area, large population, and dispersed, heterogeneous nature of research data in China, there is a dearth of comprehensive and accurate integrated assessments of the prevalence of OSA in the country. It is therefore clinically and epidemiologically important to conduct a meta-analysis, integrating data from existing studies, in order to systematically assess and estimate the prevalence of OSA in China.

The objective of this study was to conduct a systematic meta-analysis of the prevalence of obstructive sleep apnoea (OSA) in Chinese patients. A comprehensive search of the relevant literature and the application of statistical methods enabled us to derive an overall prevalence estimate and identify associated risk factors by summarising the data from several studies. To gain a deeper understanding of the prevalence of OSA in different subgroups of the Chinese population, this study conducted a meta-analysis of the prevalence of OSA in China by subgroup analysis methods based on age, gender, geographic region, year, urban/rural, and occupation.

Material and Methods

Study Design

The implementation of this systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 (PRISMA) statement.¹⁰ As the meta-analysis was based on previously published studies, no ethical statement was required for this study.

Search Strategy

A comprehensive search was conducted for relevant studies published in Chinese and English bibliographic databases, including China Knowledge Network (CNKI), Wanfang, Weipu, PubMed, Web of Science, and Embase, between 1 January 2000 and 1 October 2024. The literature search was conducted using medical subject headings (MeSH terms) and free-text terms, with keywords including "prevalence", "OSA", "obstructive sleep apnea" and "China". A combination of Boolean logic operators (eg "OR" and "AND") was employed in the search strategy. Only studies published in Chinese or English were included in the review. To ensure comprehensive coverage, we conducted a manual search for references to include reviews and relevant studies. Please refer to the supplementary tables (Supplementary Table S1-S7) for a detailed account of the search terms and strategies employed.

Inclusion and Exclusion Criteria

The following criteria were used to determine inclusion: (a) the prevalence of OSA was either reported or calculable; (b) the participants were of Chinese nationality; (c) the presence of OSA symptoms was evaluated using a standardized instrument; (d) studies that directly and/or indirectly provided the prevalence of OSA and sample sizes; and (e) published or unpublished articles were reported in either Chinese or English. The following studies were excluded from the review: (a) reviews, case reports, commentaries, letters, and editorials; (b) studies involving different diseases or disease comorbidities; (c) studies that did not provide prevalence data; (d) studies for which the full text was not available through online databases, library requests, or e-mail correspondence with the authors; and (e) studies assessed to be of moderate or low quality based on the risk of bias tool for prevalence studies.

Data Extraction

Duplicate articles were removed using reference management software (NoteExpress V4.0 and EndNote version X9.0). Two authors (YQ N and SW S) undertook an independent screening of the titles and abstracts of the collected studies, followed by the retrieval and assessment of the full-text versions of the studies in accordance with the pre-established inclusion and exclusion criteria. In the event of multiple studies utilizing the same dataset, only the study comprising the largest sample size was included to ensure the accuracy of the assessment. In the event of any disagreement, a third investigator (YL W) was consulted to facilitate a negotiated resolution or, if necessary, to make a final adjudication. The data were extracted in Microsoft Excel using a standardized format. The extracted information included the name of the first author, key outcomes (prevalence or number of cases and sample size), year of data collection, region (where the study was conducted), study site (urban versus rural), age and sex of the participants, method of sample selection (epidemiological survey methodology), and other necessary information. Furthermore, the sampling strategy was documented, including the sampling frame, randomization techniques, and the use of screening questionnaires to identify subjects at risk. The type of sleep study conducted in each study was clearly documented, as well as the definition of OSA that was applied (eg, apnoea-hypoventilation index (AHI) or respiratory disturbance index (RDI) thresholds). The prevalence of reported OSA (AHI or RDI \geq 5 events per hour) was recorded. In studies employing two-step sampling (ie, screening questionnaires followed by a sleep study), we documented whether only high-risk subjects or both high- and low-risk subjects underwent a sleep study. This was done in order to validate the weighted prevalence based on the proportion of subjects tested and found to have OSA in each risk category. Following the removal of duplicates from the initial search results, all data extraction was conducted by one evaluator (YQ N), while another evaluator (SW S) undertook a detailed examination of the extracted data and addressed any inconsistencies. Any discrepancies were resolved through discussion with the involvement of both evaluators. The data were primarily sourced from the primary literature, with supplementary information obtained through direct communication with the authors when necessary. In the event that no response was received within one month, the requested data were considered to be missing.

Quality Assessment

In order to assess the quality of the included studies, the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Studies Reporting Prevalence Data (hereafter referred to as the "JBI Checklist") was employed.¹¹ This consists of nine items, namely sample frame, sample size, and description of the sample. The following criteria were considered: sample size, subject characteristics, and environmental description, sample coverage for data analysis, the validity of the assessment method, standardization and reliability of the method of assessing the results, the accuracy of the statistical analysis, and response rate. A score of 1 was assigned for each criterion, and the evaluator determined the risk of bias by responding with one of four options: "yes", "no", "not sure", or "not applicable". This procedure allows for the identification of the cause of bias. The total RoB assessment score ranges from 0 to 9, with a higher score indicating a lower risk of bias. In this study, the results of the risk of bias assessment were categorized into three levels: low (RoB score of 8–9), medium (RoB score of 6–7) and high (RoB score of 3–5). A score of less than six out of a possible nine was deemed to indicate a low quality of study.¹² The quality assessment process was conducted by two independent evaluators (YQ N and SW S), with a third researcher (YL W) consulted in the event of any discrepancy.

Statistical Analysis

The pooled estimates of OSA prevalence for the included studies were tabulated, and the precision of the pooled results was assessed using 95% confidence intervals (CIs). The standard errors of prevalence were calculated on the basis of the prevalence of each included study in relation to the sample size. A meta-analysis was employed to derive pooled estimates of the prevalence of OSA and their 95% confidence intervals (95% CIs) for the overall sample and for each sub-cohort. The prevalence and combined estimates were displayed in forest plots. The Cochran-based chi-square Q-tests and I² tests were employed for the assessment of study heterogeneity. In instances where there was minimal evidence of heterogeneity (ie, $I^2 \leq 50\%$, heterogeneity P>0.10), a fixed-effects model was employed to generate the combined estimates. Conversely, in situations where heterogeneity was more pronounced, a random-effects model was utilized. Z-tests were employed to ascertain whether the combined rates differed significantly between cohorts. The sources of heterogeneity in prevalence estimates were explored through the use of subgroup analyses, which classified the cohorts based on a number of factors, including survey year (classified into five-year periods), sex (female and male), region (urban, rural, and mixed), geographic area (North China, Northeast China, East China, Central China, South China, Southwest China, and Northwest China), age, occupation, method of sample selection, method of sleep monitoring, and results of quality assessment. To evaluate the impact of study quality on prevalence estimates, we conducted sensitivity analyses excluding studies with Joanna Briggs Institute (JBI) scores ≤ 5 (low quality). A secondary analysis restricted inclusion to studies with JBI \geq 8 (high quality). We assessed potential publication bias through visual inspection of funnel plot symmetry, Egger's test (P<0.05). Furthermore, meta-regression analyses were conducted to investigate the sources of heterogeneity and the primary factors influencing prevalence estimates. A two-sided p-value of less than 0.05 was considered statistically significant. All data analyses were conducted using STATA version 16.0 (StataCorp LP, College Station, Texas, USA).

Results

Study Selection and Characteristics of Included Studies

A total of 2,548 relevant studies were identified through the application of search techniques across six electronic databases and grey literature. Following the removal of 390 duplicates using literature management software, 2033 records were excluded for various reasons after title and abstract screening. An assessment method that met the inclusion criteria was employed, and 125 articles were ultimately selected for further review. Following a comprehensive assessment, 62 studies were ultimately deemed eligible for inclusion (see List of Studies). The inclusion process is outlined in Figure 1. All included studies employed a cross-sectional design, with sample sizes ranging from 144 to 13,625 and a total population of 178,049 participants. The prevalence of OSA ranged from 1.2% to 88.2%. All of the included studies employed polysomnography (PSG) techniques for the identification of OSA. For further details regarding the characteristics of the included studies, please refer to Table 1.

The studies included in the review were published between 2001 and 2024 and involved a total of 178,049 subjects. Of the studies included, 14 were focused on North China, 2 on Northeast China, 22 on East China, 4 on Central China, 6 on Southwest China, 2 on Northwest China, and 12 on South China. In addition, 37 studies were conducted in urban settings, with two studies conducted in rural settings. Furthermore, 23 studies employed a balanced recruitment strategy, ensuring an equal representation of urban and rural subjects. The age range of subjects used in the studies differed. All of the included studies employed a two-step sampling process. In the initial stage of the process, individuals deemed to be at risk of developing obstructive sleep apnoea (OSA) were identified through the utilization of vernacular versions of various questionnaires. The questionnaires employed included the Snoring Symptom Screen, the Epworth Sleepiness Scale, the Berlin Questionnaire, the STOP-Bang Questionnaire, the Paediatric Sleep Questionnaire (PSQ), and a self-designed questionnaire by the investigators. In the second step, subjects were invited to participate in a sleep study based on a risk assessment, with sample sizes of either a high- versus low-risk group (n = 25) or a high-risk group only (n = 37). The final prevalence was calculated by weighted averaging the proportions of individuals tested and diagnosed with OSA in the high- and low-risk groups. In some studies, the weighted prevalence rates were not reported directly; rather,



 $\label{eq:Figure I} \mbox{ Flow chart of study selection for systematic review and meta-analysis.}$

they were extrapolated based on the number of sleep tests performed and the number of positive results in each risk group.

Of the studies included in the review, 43 employed all-night laboratory polysomnography (PSG), while the remaining 19 utilized portable sleep monitoring. With regard to the definition of apnoea, there was considerable consistency across

Author	Screening Year	Province or Municipality	Geographic Area	Region of Study	Age Range	Mean Age (SD)	Sex (M/F)	N with OSA	Total Sample Size	Prevalence Rate (%)	Sampling Method	Sampling Strategy	Diagnostic Method	OSA Diagnostic Criteria
lp et al, 2001 ¹³	1997.07–1999.04	Xianggang	SC	Urban	30–60	41.2±6.4	784/-	32	784	4.08%	RCS	Both high- and low-risk	3	AHI≥5 (sleep lab PSG)
Lin et al,2002 ¹⁴	2000.06-2001.12	Weifang	EC	Mixed	1.2–87	N/R	2026/1874	47	3900	1.21%	RS	Only high-risk	1, 2, 3	AHI ≥5 (sleep lab PSG)
SRDSG.,2003 ¹⁵	N/R	Shanghai	EC	Urban	30–99	54.8±13.5	3378/3448	247	6826	3.62%	RCS	Only high-risk	<u>2</u> , 3	AHI ≥5 (sleep lab PSG)
Zhang et al,2003 ¹⁶	N/R	Chengde	NC	Urban	30–86	48.4 ±13.17	582/586	54	1168	4.62%	RCS	Only high-risk	1, 2, 3	AHI ≥5 (portable monitor)
lp et al,2004 ¹⁷	1998.01–2000.12	Xianggang	SC	Urban	30–60	41.6 ±7.4	-/678	15	678	2.21%	RCS	Both high- and low-risk	3	AHI≥5 (sleep lab PSG)
Wang et al,2004 ¹⁸	1998.01-2001.12	Taiyuan	NC	Urban	0-100	N/R	2901/2227	179	5128	3.49%	RCS	Only high-risk	1, 2, 3	AHI ≥5 (sleep lab PSG)
Ye et al,2005 ¹⁹	N/R	Beijing	NC	Urban	40-101	N/R	-/1220	136	1220	11.15%	SCS	Both high- and low-risk	I, 2, 3	AHI≥5 (sleep lab PSG)
Li et al,2005 ²⁰	2004.03–2004.06	Changchun	NEC	Urban	20–88	43±13	1842/1806	2262	3648	62.10%	RCS	Both high- and low-risk	1, 2, 3	AHI≥5, LSaO2<90%(sleep Iab PSG)
Liang et al,2006 ²¹	2002.12–2004.06	Nanjing	EC	Urban	21–54	31.9±16.7	1063/2	20	1065	1.88%	RCS	Both high- and low-risk	I, 2, 3	AHI≥5 (sleep lab PSG)
Hou et al,2006 ²²	2003.02–2005.05	Zhuzhou	сс	Urban	6–92	N/R	2025/1591	146	3616	4.04%	RCS	Only high-risk	1, 2, 3	AHI ≥5(sleep lab PSG)
Li et al,2006 ²³	2005.08-2005.12	Guangzhou	SC	Urban	70–91	N/R	146/7	57	153	37.25%	RCS	Both high- and low-risk	3	AHI ≥5(sleep lab PSG)
Hu et al,2007 ²⁴	2004.01–2005.01	Changchun	NEC	Mixed	15–70	N/R	4589/1715	131	6304	2.08%	RCS	Both high- and low-risk	I, 2, 3	AHI ≥5 (portable monitor)
Liu et al,2007 ²⁵	2003.01-2005.03	Guangxi	SC	Mixed	14–99	39.60±17.46	5451/5080	448	10 531	4.25%	RCS	Both high- and low-risk	1, 2, 3	AHI ≥5(sleep lab PSG)

Table I Characteristic of Studies on the Prevalence of Obstructive Sleep Apnoea

Nature and Science of	
Sleep 2025:	Gong et al,20 Zou et al.20
:17	Jing et al,20 Zhang et al.20

				r					r					
Gong et al,2007 ²⁶	N/R	Shanghai	EC	Urban	30–100	63.58±15.55	867/1133	73	2000	3.65%	RCS	Only high-risk	1, 2, 3	AHI ≥5(sleep lab PSG)
Zou et al,2007 ²⁷	N/R	Shaoyang	СС	Urban	≥20	N/R	2071/1949	126	4020	3.13%	RCS	Only high-risk	1, 2, 3	AHI ≥5(sleep lab PSG)
Jing et al,2008 ²⁸	2003.07-2003.08	Chengde	NC	Mixed	N/R	N/R	646/72	30	718	4.18%	RCS	Only high-risk	1, 2, 3	AHI ≥5(sleep lab PSG)
Zhang et al,2008 ²⁹	2007.02–2007.07	Jinan	EC	Urban	3–6	4.1±1.7	395/372	17	767	2.22%	RCS	Both high- and low-risk	3, 7	AHI ≥3(sleep lab PSG)
Huang et al,2009 ³⁰	2005.01–2005.06	Wenzhou	EC	Mixed	18–72	N/R	7102/6523	446	13 625	3.27%	RCS	Only high-risk	1, 2, 3	AHI ≥5(sleep lab PSG)
Lin et al,2009 ³¹	2005.05–2008.02	Fuzhou	EC	Urban	20–95	45±16	2168/2118	205	4286	4.78%	RCS	Only high-risk	1, 2, 3	AHI ≥5(sleep lab PSG)
Ge et al,2009 ³²	2005.06-2006.12	Qindao	EC	Urban	≥20	N/R	3436/3594	237	7030	3.37%	RCS	Only high-risk	1, 3	AHI ≥5 (portable monitor)
Gao et al,2009 ³³	N/R	Wenzhou	EC	Urban	20–69	N/R	1416/584	90	2000	4.50%	RS	Only high-risk	1, 2, 3	AHI ≥5(sleep lab PSG)
Ma et al,2010 ³⁴	2006.06-2006.09	Xilinguole	NC	Rural	20–81	N/R	776/1242	325	2018	16.11%	RCS	Only high-risk	1, 2, 3	AHI ≥5 (portable monitor)
Zhang et al,2010 ³⁵	2009.03-2009.06	Huhehaote	NC	Mixed	20–63	N/R	931/84	149	1015	14.68%	RS	Both high- and low-risk	I, 2, 3	AHI ≥5(sleep lab PSG)
Lin et al,2010 ³⁶	2005.05-2008.02	Fuzhou	EC	Urban	60–95	69.0±7.6	481/423	93	904	10.29%	RCS	Only high-risk	I, 2, 3	AHI ≥5(sleep lab PSG)
Li et al,2010 ³⁷	N/R	Xianggang	SC	Urban	5~13	N/R	3260/3187	310	6447	4.81%	RCS	Both high- and low-risk	3, 7	OAHI≥I(sleep lab PSG)
Wei et al,2010 ³⁸	N/R	Beijing	NC	Urban	3~14	N/R	N/R	543	9198	5.90%	SCS	Only high-risk	3, 6	AHI ≥5 (portable monitor)
Ma et al,2011 ³⁹	2000.01-2010.12	Taiyuan	NC	Mixed	0–70	N/R	N/R	428	1004	42.63%	RCS	Both high- and low-risk	Ι, 3	AHI ≥5 (portable monitor)
Che et al,2011 ⁴⁰	2010.05-2010.12	Jinan	EC	Urban	30–97	55.1±12.5	3437/3387	272	6824	3.99%	RCS	Only high-risk	1, 2, 3	AHI ≥5(sleep lab PSG)
Jin et al,2012 ⁴¹	N/R	Guangzhou	SC	Urban	≥30	N/R	-/865	94	865	10.87%	SCS	Both high- and low-risk	3, 7	AHI ≥5(sleep lab PSG)
Xie et al,2012 ⁴²	2010.08-2011.12	Quanzhou	EC	Mixed	16-47	34.46±8.12	N/R	92	3812	2.41%	RCS	Only high-risk	I, 2, 3	AHI ≥5(sleep lab PSG)

(Continued)

Table I (Continued).

Author	Screening Year	Province or Municipality	Geographic Area	Region of Study	Age Range	Mean Age (SD)	Sex (M/F)	N with OSA	Total Sample Size	Prevalence Rate (%)	Sampling Method	Sampling Strategy	Diagnostic Method	OSA Diagnostic Criteria
Hu et al,2013 ⁴³	2009.08–2010.08	Shanghai	EC	Urban	4~7	5.73 ± 1.17	2266/1779	158	4045	3.91%	RCS	Both high- and low-risk	2, 3, 4	AHI ≥5, LSaO2≤94% (sleep Iab PSG)
Wang et al,2013 ⁴⁴	2011.09–2012.10	Chengde	NC	Urban	19–60	36.05±9.17	455/-	55	455	12.09%	RCS	Only high-risk	2, 3	AHI ≥5 (portable monitor)
Zhao et al,2013 ⁴⁵	2010.11–2011.10	Beijing	NC	Urban	14–78	31.3±12.4	2401/2587	481	4988	9.64%	RCS	Both high- and low-risk	1, 2, 3	AHI ≥5(sleep lab PSG)
Zheng et al,2013 ⁴⁶	N/R	Guangzhou	SC	Mixed	19–53	N/R	323/12	42	335	12.54%	RCS	Both high- and low-risk	2, 3	AHI ≥5 (portable monitor)
Sun et al,2014 ⁴⁷	2010.09–2012.09	Kunming	SW	Urban	20–60	N/R	1605/1480	121	3085	3.92%	RS	Both high- and low-risk	1, 2, 3	AHI ≥5(sleep lab PSG)
Hu et al,2014 ⁴⁸	2012.04–2013.12	Shanghai	EC	Urban	20–95	48.3 ± 14.0	3552/3290	349	6842	5.10%	RCS	Both high- and low-risk	1, 2, 3, 4	AHI ≥5, LSaO2<90% (sleep Iab PSG)
Peng et al,2014 ⁴⁹	2012.12	Guangzhou	sc	Urban	3~6	N/R	724/602	96	1326	7.24%	RCS	Only high-risk	3, 7	AHI ≥5, LSaO2<92% (sleep Iab PSG)
Chen et al,2014 ⁵⁰	2011.06-2012.05	Chengdu	SW	Urban	23–88	40.92±15.54	968/721	94	1689	5.57%	RCS	Only high-risk	1, 2, 3	AHI ≥5 (portable monitor)
Liu et al,2014 ⁵¹	N/R	Guangxi	SC	Mixed	14–99	N/R	5594/5225	444	10 819	4.10%	RCS	Both high- and low-risk	1, 2, 3	AHI ≥5 (portable monitor)
Wu et al,2014 ⁵²	2011.11–2013.10	Honghe	SVV	Mixed	≥20	N/R	N/R	62	1566	3.96%	RCS	Only high-risk	3, 7	AHI ≥5(sleep lab PSG)
Ng et al,2015 ⁵³	2007.9–2010.8	Xianggang	SC	Urban	≥60	73.9±7.5	207/612	33	819	4.03%	RSS	Both high- and low-risk	2, 3	AHI ≥5 (portable monitor)
Wu et al,2016 ⁵⁴	2007.03–2014.10	Guiyang	SW	Mixed	19–60	36.02±9.09	510/57	155	567	27.34%	RS	Both high- and low-risk	2, 3	AHI ≥5(sleep lab PSG)

Nature a	
nd	
Science	
<u>ç</u>	
Sleep	
2025:I	

Jin et al,2016 ⁵⁵	2013.06-2014.12	Beijing	NC	Urban	30–60	N/R	619/507	82	1126	7.28%	RCS	Only high-risk	1, 2, 3	AHI ≥5(sleep lab PSG)
Wang et al,2016 ⁵⁶	2014.03-2014.09	Wuhan	сс	Mixed	24–58	36.0±5.6	389/-	46	389	11.83%	RCS	Only high-risk	1, 2, 3	AHI ≥5 (portable monitor)
Liu et al,2016 ⁵⁷	2014.10-2015.09	Shanghai	EC	Mixed	25–53	40.4±6.0	823/-	111	823	13.49%	RCS	Only high-risk	1, 2, 3	AHI ≥5 (portable monitor)
Su et al,2016 ⁵⁸	N/R	Dongying	EC	Urban	60–89	69±5.4	534/400	304	934	32.55%	RCS	Only high-risk	3, 4	AHI ≥5(sleep lab PSG)
Ma et al,2017 ⁵⁹	2016.09–2016.12	Penglai	EC	Mixed	30–59	N/R	1398/1110	68	2508	2.71%	RS	Only high-risk	3, 7	AHI ≥5(sleep lab PSG)
Zhang et al,2017 ⁶⁰	N/R	Nantong	EC	Mixed	≥30	N/R	N/R	118	3780	3.12%	RCS	Only high-risk	1, 2, 3	AHI ≥5(sleep lab PSG)
Hu et al,2017 ⁶¹	N/R	Ningxia	NW	Mixed	≥20	N/R	971/789	174	1760	9.89%	SCS	Only high-risk	1, 2, 3	AHI ≥5, LSaO2≤90% (portable monitor)
Deng et al,2018 ⁶²	2016.07–2017.10	Jingmen	сс	Urban	18–78	31.3±12.4	-/1961	518	1961	26.42%	RCS	Only high-risk	1, 2, 3	AHI ≥5(sleep lab PSG)
Cao et al,2018 ⁶³	2016.03-2016.04	Huhehaote	NC	Rural	17–29	N/R	200/-	32	200	16.00%	RCS	Both high- and low-risk	Ι, 3	AHI ≥5(sleep lab PSG)
Zhang et al,2018 ⁶⁴	2015.07-2017.12	Taiyuan	SW	Urban	≥18	N/R	815/911	286	1726	16.57%	RCS	Both high- and low-risk	1, 2, 3	AHI ≥5 (portable monitor)
Zhang et al,2019 ⁶⁵	2018.01–2018.06	Yibin	NC	Urban	6~12	9.6±1.2	1101/892	78	1903	4.10%	SCS	Only high-risk	3, 4	AHI ≥5, LSaO2<92% (sleep lab PSG)
Xie et al,2020 ⁶⁶	2016.08-2018.12	Nanjing	EC	Mixed	20-49	33.19±8.27	3634/-	146	3643	4.01%	RCS	Only high-risk	1, 2, 3	AHI ≥5(sleep lab PSG)
Hong et al,2020 ⁶⁷	2017.07-2017.09	Guangzhou	SC	Urban	22–63	41±9	799/237	103	1036	9.94%	RS	Only high-risk	2, 3, 4	AHI ≥5 (portable monitor)
Yang et al,2021 ⁶⁸	2017.10-2019.05	Qinhuangdao	NC	Mixed	19–85	N/R	114/30	25	144	17.36%	RCS	Only high-risk	1, 2, 3	AHI ≥5(sleep lab PSG)
Ma et al,2022 ⁶⁹	2020.01–2020.12	Xining	NW	Mixed	42–76	N/R	486/172	302	658	45.90%	RCS	Only high-risk	3, 5	AHI ≥5 (portable monitor)
Liu et al,2022 ⁷⁰	2020.09–2020.12	Jinan	EC	Mixed	23–52	32.18±7.93	302/45	47	347	13.54%	RCS	Only high-risk	2, 3	AHI ≥5 (portable monitor)
Sun et al,2023 ⁷¹	2017.09–2017.11	Wuhu	EC	Mixed	≥20	N/R	N/R	46	808	5.69%	SCS	Only high-risk	3	AHI ≥5(sleep lab PSG)

(Continued)

Table I (Continued).

Author	Screening Year	Province or Municipality	Geographic Area	Region of Study	Age Range	Mean Age (SD)	Sex (M/F)	N with OSA	Total Sample Size	Prevalence Rate (%)	Sampling Method	Sampling Strategy	Diagnostic Method	OSA Diagnostic Criteria
Guo et al,2023 ⁷²	2021.04-2021.05	Guangzhou	sc	Urban	41–67	53.81±12.71	1098/2552	1119	3650	30.66%	SCS	Both high- and low-risk	2, 3, 5	ODI ≥7, AHI ≥5 (portable monitor)
Liu et al,2024 ⁷³	2023.03-2023.06	Deyang	SW	Urban	3~6	4.8±0.9	801/607	64	1408	4.55%	RCS	Only high-risk	3, 6	OAHI>I (sleep lab PSG)
Zheng et al,2024 ⁷⁴	2012.01–2021.10	Shanghai	EC	Mixed	≥18	N/R	879/276	1019	1155	88.23%	RCS	Both high- and low-risk	Ι, 3	AHI ≥5(sleep lab PSG)

Notes: Diagnostic Method: I, Symptom Screen for Snoring; 2, Epworth Sleepiness Scale; 3, Polysomnography; 4, Berlin Questionnaire; 5, STOP-Bang Questionnaire; 6, Pediatric Sleep Questionnaire (PSQ); 7, Questions Designed by the Investigator.

Abbreviations: Geographic Area: NC, North China; NEC, Northeast China; EC, East China; CC, Central China; SW, Southwest China; NW, Northwest China; SC, South China;

Sampling Method: RCS, Random Cluster Sampling; SCS, Stratified Cluster Sampling; RS, Random Sampling; RSS, Random Stratified Sampling; OSA Diagnostic Criteria: AHI, Apnea-Hypopnea Index, events/h; LSaO2, Lowest Oxygen Saturation; OAHI, Obstructive Apnea-Hypopnea Index, events/h; ODI, Oxygen Desaturation Index, events/h; N/R, not reported.

studies, with the condition being defined as a reduction in airflow of either 100% or 90%, lasting for a minimum of 10 seconds. In contrast, the definition of hypoventilation employed the apnoea-hypoventilation index (AHI), which is the sum of apnoea and hypoventilation events per hour of sleep, with a threshold of \geq 5 events/h.

Quality Assessment

The quality of the included prevalence studies was evaluated in accordance with the JBI checklist, with scores ranging from 3 to 9 out of 9 (see Table 2 for details). Of the studies included, 20 were deemed to be of high quality, as indicated by a score of 8 or 9 on the JBI checklist. Thirty studies were classified as moderate quality, with a score of 6 or 7, while

Author, Year of Publication	Ι	2	3	4	5	6	7	8	9
lp et al, 2001 ¹³	No	Yes	Yes	Yes	No	Yes	Yes	Yes	No
Lin et al,2002 ¹⁴	Yes	No	Yes	Yes	No	Yes	Yes	Yes	No
SRDSG.,2003 ¹⁵	Yes	No	Yes	Yes	No	Yes	Yes	Yes	Yes
Zhang et al,2003 ¹⁶	Yes	No	Yes	Yes	No	Yes	Yes	Yes	Yes
lp et al,2004 ¹⁷	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No
Wang et al,2004 ¹⁸	Yes	No	Yes	Yes	No	Yes	Yes	No	Yes
Ye et al,2005 ¹⁹	Yes								
Li et al,2005 ²⁰	Yes	No	Yes						
Liang et al,2006 ²¹	No	Yes							
Hou et al,2006 ²²	Yes	No	Yes	Yes	No	Yes	Yes	No	Yes
Li et al,2006 ²³	No	Yes	Yes	No	Yes	Yes	Yes	No	No
Hu et al,2007 ²⁴	No	Yes	Yes	Yes	No	Yes	Yes	No	Yes
Liu et al,2007 ²⁵	Yes								
Gong et al,2007 ²⁶	Yes	No	Yes	Yes	No	Yes	Yes	Yes	Yes
Zou et al,2007 ²⁷	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No
Jing et al,2008 ²⁸	No	No	Yes	Yes	No	Yes	Yes	Yes	No
Zhang et al,2008 ²⁹	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes
Huang et al,2009 ³⁰	Yes	No	Yes	Yes	No	Yes	Yes	Yes	Yes
Lin et al,2009 ³¹	Yes	No	Yes	Yes	No	Yes	Yes	Yes	Yes
Ge et al,2009 ³²	Yes	No	Yes						
Gao et al,2009 ³³	Yes	No	Yes	Yes	No	Yes	Yes	No	No
Ma et al,2010 ³⁴	Yes	No	Yes	Yes	No	Yes	Yes	Yes	Yes
Zhang et al,2010 ³⁵	No	Yes							
Lin et al,2010 ³⁶	Yes	No	Yes	Yes	No	Yes	Yes	Yes	No
Li et al,2010 ³⁷	Yes								
Wei et al,2010 ³⁸	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No
Ma et al,2011 ³⁹	No	Yes	Yes	No	No	Yes	Yes	No	No
Che et al,2011 ⁴⁰	Yes	No	Yes	Yes	No	Yes	Yes	No	Yes
Jin et al,2012 ⁴¹	Yes								
Xie et al,2012 ⁴²	No	No	Yes	Yes	No	Yes	Yes	No	Yes
Hu et al,2013 ⁴³	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes
Wang et al,2013 ⁴⁴	No	No	Yes	Yes	No	Yes	Yes	Yes	No
Zhao et al,2013 ⁴⁵	Yes								
Zheng et al,2013 ⁴⁶	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes
Sun et al,2014 ⁴⁷	No	Yes							
Hu et al,2014 ⁴⁸	Yes								
Peng et al,2014 ⁴⁹	Yes	No	Yes	Yes	No	Yes	Yes	Yes	Yes
Chen et al,2014 ⁵⁰	No	No	Yes						

Table 2 Quality Assessments Using Joanna Briggs Institute Prevalence CriticalAppraisal Tool (JBIPCAT)

(Continued)

Author, Year of Publication	I	2	3	4	5	6	7	8	9
Liu et al,2014 ⁵¹	Yes								
Wu et al,2014 ⁵²	Yes	No	Yes	Yes	No	Yes	Yes	Yes	Yes
Ng et al,2015 ⁵³	Yes								
Wu et al,2016 ⁵⁴	No	Yes							
Jin et al,2016 ⁵⁵	Yes	No	Yes	Yes	No	Yes	Yes	Yes	Yes
Wang et al,2016 ⁵⁶	No	No	Yes	Yes	No	Yes	Yes	Yes	No
Liu et al,2016 ⁵⁷	No	No	Yes	Yes	No	Yes	Yes	Yes	No
Su et al,2016 ⁵⁸	Yes	No	Yes	Yes	No	Yes	Yes	Yes	Yes
Ma et al,2017 ⁵⁹	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No
Zhang et al,2017 ⁶⁰	Yes	No	Yes	Yes	No	Yes	Yes	Yes	Yes
Hu et al,2017 ⁶¹	Yes	No	Yes	Yes	No	Yes	Yes	Yes	Yes
Deng et al,2018 ⁶²	Yes	No	Yes	Yes	No	Yes	Yes	Yes	Yes
Cao et al,2018 ⁶³	No	Yes							
Zhang et al,2018 ⁶⁴	Yes								
Zhang et al,2019 ⁶⁵	Yes	No	Yes	Yes	No	Yes	Yes	Yes	Yes
Xie et al,2020 ⁶⁶	No	No	Yes	Yes	No	Yes	Yes	Yes	No
Hong et al,2020 ⁶⁷	Yes	No	Yes						
Yang et al,2021 ⁶⁸	No	No	Yes	Yes	No	Yes	Yes	No	No
Ma et al,2022 ⁶⁹	No	No	Yes	Yes	No	Yes	Yes	No	No
Liu et al,2022 ⁷⁰	No	No	Yes	Yes	No	Yes	Yes	No	Yes
Sun et al,2023 ⁷¹	Yes	No	Yes	Yes	No	Yes	Yes	Yes	Yes
Guo et al,2023 ⁷²	Yes								
Liu et al,2024 ⁷³	Yes	No	Yes	Yes	No	Yes	Yes	Yes	Yes
Zheng et al,2024 ⁷⁴	No	Yes	No						

Table 2 (Continued).



These questions can be answered either with a yes, no, unclear, or not applicable.

12 studies were rated as low quality, with a score of 3 or 5. All studies had an appropriate sample size and employed validated methods to reliably diagnose obstructive sleep apnoea (OSA) in all subjects.

The two most prevalent issues encountered during the assessment were the inappropriate sampling process (n=37) and low sample coverage (n=38). Twelve of the studies had quality scores below 5. The primary reasons for this included inadequate sample size, sampling bias, low sample coverage for data analysis, and poor standardization and reliability of methods for assessing outcomes. Furthermore, the studies lacked sufficient data on the percentage of incomplete data and the completeness of data collection. The overall quality of the included studies was deemed acceptable, although there are still some areas that require improvement.

Pooled Prevalence of Obstructive Sleep Apnoea

Overall

The 62 included studies demonstrated an overall prevalence of obstructive sleep apnoea (OSA) that ranged from 1.2% to 88.2%. The random-effects pooled estimate of the prevalence of OSA in China was 11.8% (95% CI: 10.1–13.4%) (Figure 2), with high heterogeneity (I^2 = 99.7%, P<0.001). No apparent publication bias was observed via funnel plot (Supplementary Figure S10) and Egger's test (P=0.065).

Chudu	Evente	Total	(059/ CI)	10
Siduy	Events	rotar	(90% CI)	V
lp et al., 2001	32	784	0.041 (0.027, 0.055)	
Lin et al.,2002	47	3900	0.012 (0.009, 0.015)	
SRDSG.,2003	247	6826	0.036 (0.032, 0.041)	
Zhang et al.,2003	54	1168	0.046 (0.034, 0.058)	
lp et al.,2004	15	678	0.022 (0.011, 0.033)	
Wang et al.,2004	179	5128	0.035 (0.030, 0.040)	
Ye et al.,2005	136	1220	0.111 (0.094, 0.129)	
Li et al.,2005	2262	3648	0.620 (0.604, 0.636)	
Liang et al.,2006	20	1065	0.019 (0.011, 0.027)	
Hou et al.,2006	146	3616	0.040 (0.034, 0.047)	
Li et al.,2006	57	153	0.373 (0.296, 0.449)	
Hu et al.,2007	131	6304	0.021 (0.017, 0.024)	
Liu et al.,2007	448	10531	0.043 (0.039, 0.046)	
Gong et al.,2007	73	2000	0.036 (0.028, 0.045)	
Zou et al.,2007	126	4020	0.031 (0.026, 0.037)	
Jing et al.,2008	30	718	0.042 (0.027, 0.056)	
Zhang et al.,2008	17	767	0.022 (0.012, 0.033)	
Huang et al.,2009	446	13625	0.033 (0.030, 0.036)	
Lin et al.,2009	205	4286	0.048 (0.041, 0.054)	
Ge et al.,2009	237	7030	0.034 (0.029, 0.038)	
Gao et al.,2009	90	2000	0.045 (0.036, 0.054)	
Ma et al.,2010	325	2018	0.161 (0.145. 0.177)	
Zhang et al. 2010	149	1015	0.147 (0.125. 0.169)	
Lin et al.,2010	93	904	0.103 (0.083. 0.123)	
Li et al2010	310	6447	0.048 (0.043, 0.053)	
Wei et al. 2010	543	9198	0.059 (0.054, 0.064)	
Maletal 2011	428	1004		
Che et al. 2011	272	6824	0.040 (0.035, 0.045)	
lin et al. 2012	94	865		
Xie et al. 2012	92	3812		
Huetal 2013	158	4045		
Wang et al. 2013	55	455		
Zhao et al. 2013	481	4988		
Zheng et al. 2013	42	335	0.125 (0.000, 0.161)	
Sun et al. 2014	121	3085		
Huetal 2014	349	6842		
Pena et al 2014	96	1326		
Chen et al. 2014	94	1689		
Liuetal 2014	444	10819		
Mu et al. 2014	62	1566		
Na et al 2015	33	819		
Mu et al. 2016	155	567		
lin et al 2016	82	1126		
Mang of al. 2016	46	220		
liu et al 2016	111	823		
Suptal 2016	304	023		
Ou et al., 2010 Ma of al. 2017	304 60	2509		
7hand et al.,2017	110	2000		
∠nang et al.,∠017 ⊔u at al. 2018	174	1760		
Dencietal 2019	510	1961		
	210	200		
7 hand at al 2010	3Z	1706		
Zhang et al.,2010	∠00 70	1002		
Zinally et al.,2019	10	1903		
Are et al.,2020	140	1026		
Vang at al.,2020	103	144		
nany et al.,2021 Maiotial 2022	20	144		
waetal.,2022	302	000 -		
Liu et al., 2022	4/	34/		
Sun et al.,2023	46	808		
Guo et al.,2023	1119	3650	0.307 (0.292, 0.322)	
LILLET AL 2024	64	1408		
71	1010	1155		
Zheng et al.,2024	1013			



Subgroup Analysis (Table 3)

Gender and Age

The results of our analyses demonstrated a significantly higher prevalence of obstructive sleep apnoea (OSA) in males compared to females (11.1% vs 6.0%, P < 0.001) (Supplementary Figure S2). Furthermore, the prevalence of OSA increased with age in all age groups (Supplementary Figure S5), as follows: the prevalence in the \leq 12 years group was 6.0% (95% CI: 3.5–9.0%), and the prevalence in the 13–17 years group was 7.1% (95% CI: 3.4–12. The prevalence of

Table 3 Subgroup	Analysis of th	e Source of Heter	ogeneity of	Included Studies
iable & dubgioup	7 4141/010 01 01		ogenercy of	included ocudies

Study	Number of	N with	Total Samula Siza	Heterogeneity,	Pooled Prevalence	Q	Ρ
characteristics	Studies	UJA	Sample Size	T (//)(F)	(75% CI), %		
Survey period							
2000–2005	8	2972	23.352	99.9 (<0.001)	8.1 (0.7, 22.5)	6635.056	<0.001
2006–2010	20	3876	86.566	97.9 (<0.001)	5.5 (4.4, 6.6)	915.966	<0.001
2011-2015	13	2391	37.605	99.1 (<0.001)	8.2 (5.4, 11.4)	1291.221	<0.001
2016–2020	14	2221	22.356	99.2 (<0.001)	11.8 (7.3, 17.2)	1701.372	<0.001
2021–2024	7	2622	8170	99.8 (<0.001)	26.9 (7.4, 53.0)	3151.441	<0.001
Overall	62	14,082	178.049	99.7 (<0.001)	11.8 (10.1, 13.4)	18.245.607	<0.001
Sub-groups						14.518	0.006
Sex (M/F)							
Male	48	11,908	140,458	99.7 (<0.001)	. (8. , 4.5)	17,102.830	<0.001
Female	40	9061	143.758	99.6 (<0.001)	6.0 (4.2, 8.1)	9267.235	<0.001
Overall	88	20.969	284.216	99.7 (<0.001)	8.6 (6.9, 10.5)	26.626.375	<0.001
Sub-groups						7.781	0.005
Region of Study							
Urban	37	9149	105.620	99.6 (<0.001)	8.3 (5.7, 11.4)	10.220.355	<0.001
Rural	2	357	2218	Not applicable	16.0 (14.5, 17.6)	Not	Not
						applicable	applicable
Mixed	23	4576	70.211	99.7 (<0.001)	11.7 (7.5, 16.6)	7492.273	<0.001
Overall	62	14,082	178.049	99.7 (<0.001)	.8 (0.1, 3.4)	18.245.60	<0.001
Sub-groups						19.670	<0.001
Geographic Area							
NC	14	2805	30,108	99.1 (<0.001)	.8 (8.1, 6.1)	1380.548	<0.001
NEC	2	2393	9952	Not applicable	16.9 (16.2, 17.7)	Not	Not
						applicable	applicable
EC	22	4205	77,924	99.6 (<0.001)	7.4 (4.5, 10.8)	5839.005	<0.001
CC	4	836	9986	99.6 (<0.001)	9.7 (2.2, 21.8)	782.091	<0.001
SC	12	2793	37.443	99.5 (<0.001)	9.2 (5.3, 14.0)	2046.748	<0.001
SW	6	574	10.218	98.1 (<0.001)	6.9 (3.7, 10.9)	256.509	<0.001
NW	2	476	2418	Not applicable	17.8 (16.3, 19.3)	Not	Not
						applicable	applicable
Overall	62	14.082	178.049	99.7 (<0.001)	.8 (0.1, 3.4)	18.245.607	<0.001
Sub-groups						57.943	<0.001
Age Range							
≤12	11	2066	38.742	99.2 (<0.001)	6.0 (3.5, 9.0)	1244.818	<0.001
13–17	6	1692	34.998	99.6 (<0.001)	7.1 (3.4, 12.0)	1175.662	<0.001
18–39	46	10.631	143.076	99.7 (<0.001)	9.1 (6.5, 12.1)	15.123.745	<0.001
40–64	45	11.733	127.845	99.7 (<0.001)	11.3 (8.0, 15.0)	17.483.055	<0.001
65–85	32	10.328	111.200	99.8 (<0.001)	12.3 (8.2, 17.1)	16.069.149	<0.001
≥86	14	2424	53.231	96.8 (<0.001)	6.0 (4.9, 7.3)	407.532	<0.001
Overall	154	38,874	509.092	99.7 (<0.001)	.8 (0.1, 3.4)	52.650.652	<0.001
Sub-groups						18.595	0.002
Careers							
Civil Servants	3	534	9004	Not applicable	7.3 (4.6, 10.5)	Not	Not
						applicable	applicable
Drivers	6	550	3476	91.5 (<0.001)	15.3 (11.3, 19.8)	58.850	<0.001
Clerks	2	602	8073	Not applicable	7.2 (6.6, 7.8)	Not	Not
						applicable	applicable
Pilots	I	20	1065	Not applicable	1.9 (1.2, 2.9)	Not	Not
						applicable	applicable

(Continued)

Study	Number of	N with	Total	Heterogeneity,	Pooled Prevalence	Q	Ρ
characteristics	Studies	OSA	Sample Size	l ² (%) (P)	(95% CI), %		
Soldiers	2	238	7455	Not applicable	3.1 (2.8, 3.6)	Not	Not
						applicable	applicable
Not reported	48	12.138	148.976	99.7 (<0.001)	10.0 (7.2, 13.1)	17.469.920	<0.001
Overall	62	14.082	178.049	99.7 (<0.001)	.8 (0.1, 3.4)	18.245.607	<0.001
sub-groups						218.151	<0.001
Sleep monitoring							
methods							
In-lab	43	9508	126.821	99.7 (<0.001)	8.7 (6.0, 11.8)	13.996.658	<0.001
Portable	19	4574	51.228	99.6 (<0.001)	12.2 (8.0, 17.0)	4113.820	<0.001
Overall	62	14.082	178.049	99.7 (<0.001)	.8 (0.1, 3.4)	18.245.607	<0.001
sub-groups						1.683	0.195
RoB score							
8–9	20	6954	70.365	99.8 (<0.001)	10.2 (5.8, 15.7)	8750.664	<0.001
6–7	30	5699	93.538	99.6 (<0.001)	7.6 (5.1, 10.5)	7036.249	<0.001
3–5	12	1429	14.146	99.4 (<0.001)	15.0 (7.8, 23.9)	1850.873	<0.001
Overall	62	14.082	178.049	99.7 (<0.001)	.8 (0.1, 3.4)	18.245.607	<0.001
sub-groups						3.775	0.151
Sampling Strategy							
Both high- and low-	25	8338	72.712	99.8 (<0.001)	13.6 (8.1, 20.3)	13.800.369	<0.001
risk							
Only high-risk	37	5744	105.337	98.9 (<0.001)	7.4 (5.9, 9.0)	3320.444	<0.001
Overall	62	14.082	178.049	99.7 (<0.001)	.8 (0.1, 3.4)	18.245.607	<0.001
sub-groups						4.609	0.032

Table 3 (Continued).

Abbreviations: NC, North China; NEC, Northeast China; EC, East China; CC, Central China; SW, Southwest China; NW, Northwest China; SC, South China;

OSA was 9.1% (95% CI: 6.5–12.1%) in the 18–39 years age group, 11.3% (95% CI: 8.0–15.0%) in the 40–64 years age group, 12.3% (95% CI: 8.2–17.1%) in the 65–85 years age group, and 6.0% (95% CI: 4.9–7.3%) in the \geq 86 years age group. It is noteworthy that the lowest prevalence was observed in the \leq 12 years age group (6.0%), while the highest prevalence was observed in the 65–85 years age group (12.3%). This age-related pattern was further corroborated by subgroup analyses excluding pediatric studies (n=7/62). The pooled prevalence in adults reached 13.0% (9.0–17.0%), significantly exceeding the 5.0% (4.0–6.0%) observed in children (Psubgroup difference < 0.001). Detailed forest plots of age-stratified estimates are provided in <u>Supplementary Figure S5</u>.

Year of Investigation

The results of the meta-analysis indicated a tendency for the prevalence of obstructive sleep apnoea to increase annually throughout the study period (Supplementary Figure S1). Specifically, the prevalence was 8.1% (95% CI: 0.7–22.5%) between 2000–2005; 5.5% (95% CI: 4.4–6.6%) between 2006–2010; 8.2% (95% CI: 5.4–11.4%) between 2011–2015; and increased significantly to 11.8% between 2016–2020 (95% CI: 7.3–17.2%); and 26.9% (95% CI: 7.4–53.0%) in 2021–2024, indicating a notable rise in the prevalence of OSA in recent years.

Geographic Location and Study Setting

In the geographic analysis, the pooled prevalence of obstructive sleep apnoea (OSA) was 8.3% (95% CI: 5.7–11.4%) in the urban population, whereas the mixed urban-rural population exhibited a relatively elevated prevalence of 11.7% (95% CI: 7.5–16.6%). The two studies conducted in rural areas demonstrated a prevalence of 16.0% (95% CI: 14.5–17.6%), thereby further emphasizing the impact of urban-rural differences on the prevalence of OSA (see <u>Supplementary Figure</u> <u>S3</u>). The lowest prevalence was observed in the South West (6.9%, 95% CI: 3.7–10.9%), while the highest was seen in

the North West (17.8%, 95% CI: 16.3–19.3%). The prevalence rates in other regions were as follows: 11.8% (95% CI: 8.1–16.1%) in North China, 16.9% (95% CI: 16.2–17.7%) in Northeast China, 7.4% (95% CI: 4.5–10.8%) in East China, 9.7% (95% CI: 2.2–21.8%) in Central China, and 9.2% (95% CI: 5.3–14.0%) (see <u>Supplementary Figure S4</u>).

Occupation

With regard to occupational differences, the prevalence of obstructive sleep apnoea (OSA) was 7.3% (95% confidence interval (CI): 4.6–10.5%) for civil servants, while drivers exhibited a significantly higher prevalence of 15.3% (95% CI: 11.3–19.8%). In contrast, the prevalence among clerks was 7.2% (95% CI: 6.6–7.8%), while pilots and soldiers exhibited relatively low prevalence rates of 1.9% (95% CI: 1.2–2.9%) and 3.1% (95% CI: 2.8–3.6%), respectively. The group prevalence without reported occupation was 10.0% (95% CI: 7.2–13.1%) (see Supplementary Figure S6).

Analyses According to Sleep Monitoring Modality

A subgroup analysis of different sleep monitoring modalities revealed that studies utilizing laboratory and portable sleep studies exhibited comparable combined prevalence rates of 8.7% (95% CI: 6.0–11.8%) and 12.2% (95% CI: 8.0–17.0%), respectively. This suggests that the prevalence trend of OSA remained consistent irrespective of the monitoring modality (see <u>Supplementary Figure S7</u>).

Analysis Based on Quality Assessment Results

Following the categorization of the quality of the studies, it was observed that the combined prevalence rates were comparable for studies with quality assessment results of high, medium, and low quality, at 10.2% (95% CI: 5.8–15.7%), 7.6% (95% CI: 5.1–10.5%), and 15.0% (95% CI: 7.8–23.9%), respectively. Please refer to Supplementary Figure S9 for further details.

Analyses According to Sampling Strategy

The proportion of studies that included both high- and low-risk groups was significantly higher than the proportion of studies that included only high-risk groups (13.6% vs 7.4%, P < 0.001) (Supplementary Figure S8).

Significance Tests for Subgroup Analyses

Please refer to <u>Supplementary Table S8</u> for details of the significance tests applied to subgroup analyses of the prevalence of obstructive sleep apnoea (OSA) in China.

Sensitivity Analyses

Sensitivity Analysis of Methodological Quality Influence

Sensitivity analysis excluding low-quality studies (n=12) reduced the pooled prevalence from 11.8% (95% CI: 10.1-13.4%) to 8.6% (95% CI: 6.3-11.3%), with heterogeneity decreasing from I²=99.7% to 99.3%. Restricting analysis to high-quality studies (n=20) further lowered the estimate to 8.1% (95% CI: 5.8-10.8%). (Figures 3 and 4) This quality-prevalence gradient primarily stemmed from methodological flaws in low-quality studies. This reduction underscores the importance of methodological quality in prevalence estimates and confirms that lower quality studies have the potential to bias the overall findings.

Sensitivity Analysis Excluding Extreme Outliers

To assess the robustness of our estimates, we conducted sensitivity analyses excluding studies with prevalence values beyond ± 3 SD from the pooled mean (Zheng et al, 2024; Li et al, 2005; Ma et al, 2022). The revised analysis incorporated 59 studies, reduced heterogeneity (I²=99.7% \rightarrow 99.1%) and modestly lowered the estimate to 7.8% (95% CI: 6.5–9.2%), suggesting these studies disproportionately influenced the upper confidence limit. (Supplementary Figure S11)

Sensitivity Analysis Excluding Studies Restricted to High-Risk Populations

In conducting sensitivity analyses, studies in which sleep studies were conducted exclusively in high-risk populations identified by questionnaire were excluded (Figure 5). Following the analysis of studies encompassing both high- and low-

Ye et al. 2005 136 120 Li et al. 2005 282 344 0.611 (0.094, 0.130) 2.00 Li et al. 2007 448 1051 0.019 (0.012, 0.029) 2.00 Jamag et al. 2008 237 7.03 0.022 (0.094, 0.038) 2.01 Carl and et al. 2007 348 1051 0.024 (0.012, 0.029) 10.022 (0.094, 0.038) 2.01 Carl and et al. 2010 310 6447 0.024 (0.012, 0.029) 1.04 (0.026, 0.010) 1.64 (0.026, 0.038) 2.01 Li et al. 2010 310 6447 0.044 (0.026, 0.044) 1.05 0.046 (0.048, 0.045) 2.01 Sun et al. 2014 349 6462 0.056 (0.068, 0.105) 2.01 0.051 (0.046, 0.056) 2.01 Vu et al. 2014 349 6442 0.051 (0.022, 0.056) 1.05 2.00 0.051 (0.022, 0.056) 1.05 0.040 (0.022, 0.056) 1.05 1.044 1.0012, 0.022, 0.026 1.05 1.044 1.0012, 0.027,	Study	Events	Total	ES (95% CI)	% Weight
Tet al., 2005 120 1220 0.0111 0.024 0.0131 0.019		126	1220		2.00
Lit al. 2003 2222 3848 0.027 (0.024, 0.034) 2.03 2.01 Liu et al. 2007 448 10631 2.01 0.043 (0.038, 0.047) 2.01 Jang et al. 2008 17 767 0.024 (0.033, 0.038) 2.01 Ge et al. 2008 17 767 0.024 (0.033, 0.038) 2.01 Jang et al. 2008 17 767 0.034 (0.033, 0.038) 2.01 Jang et al. 2010 310 6447 0.044 (0.033, 0.043) 1.98 Jan et al. 2011 188 4045 0.096 (0.088, 0.016) 2.01 Jan et al. 2014 144 4088 0.096 (0.088, 0.016) 2.01 Jan et al. 2014 144 1088 0.096 (0.088, 0.016) 2.01 Jan et al. 2014 144 1089 0.040 (0.028, 0.057) 1.98 Que et al. 2016 155 667 0.040 (0.028, 0.057) 1.98 Que et al. 2014 144 10819 0.041 (0.028, 0.057) 1.99 Zhang et al. 2018 176 1.000 0.099 (0.022, 0.14) 2.01 Jan et al. 2014 122 774 0.021 (0.028, 0.16)	re et al.,2005	130		0.111 (0.094, 0.130)	2.00
Lang et al. 2006 4.0 1085 4.0	Li et al.,2005	2262			2.01
La et al., 2007 448 102-31 Canage et al., 2008 17 767 Ge et al., 2009 237 7030 Canage et al., 2010 149 1015 Li et al., 2010 310 6447 Jun et al., 2011 349 Hu et al., 2013 158 4045 Sun et al., 2014 121 365 Sun et al., 2016 155 Sun et al., 2016 155 Sun et al., 2016 125 Can et al. 2018 122 Can et al. 2017 136 Sun et al. 2004 179 Sun et al. 2007 126 400 Can et al. 2017	Liang et al.,2006	20	1065	0.019 (0.012, 0.029)	2.00
Zhang et al. 2006 17 767 0.022 (0.013, 0.038) 195 Canag et al. 2010 149 1015 0.047 (0.126, 0.170) 196 Li et al. 2010 310 6447 0.048 (0.030, 0.054) 201 Jin et al. 2011 158 4045 0.099 (0.080, 0.045) 201 Zhao et al. 2013 168 4045 0.099 (0.080, 0.045) 201 Sun et al. 2014 121 3085 0.099 (0.080, 0.045) 201 Sun et al. 2014 124 3085 0.099 (0.080, 0.045) 201 Sun et al. 2014 124 3085 0.091 (0.027, 0.045) 201 Via et al. 2014 444 10819 0.051 (0.046, 0.056) 201 Via et al. 2016 132 200 0.273 (0.237, 0.312) 188 Cao et al. 2023 1119 3650 0.027 (0.22, 0.22) 201 Grao et al. 2023 1139 3600 0.027 (0.22, 0.22) 201 Grao et al. 2023 1139 3600 0.027 (0.22, 0.22) 201 Grao et al. 2020 <td>Liu et al.,2007</td> <td>448</td> <td>10531</td> <td>0.043 (0.039, 0.047)</td> <td>2.01</td>	Liu et al.,2007	448	10531	0.043 (0.039, 0.047)	2.01
Ge et al.,2009 237 703 0.034 (0050, 0.038) 201 Liet al.,2010 310 6447 0.046 (0.043, 0.054) 201 June tal.,2012 94 865 0.048 (0.043, 0.054) 201 June tal.,2013 158 4045 0.039 (0.033, 0.045) 201 San et al.,2014 244 6862 0.039 (0.033, 0.047) 201 Lue tal.,2014 349 6842 0.039 (0.033, 0.047) 201 Lue tal.,2014 449 6842 0.031 (0.046, 0.055) 201 Lue tal.,2016 155 657 0.027 (0.027, 0.026, 0.037, 0.022, 0.041, 0.027, 0.025 0.041 (0.028, 0.050, 0.000, 0.027, 0.029, 0.027, 0.027, 0.028, 0.040, 0.020, 0.027, 0.028, 0.040, 0.020, 0.027, 0.028, 0.040, 0.020, 0.027, 0.028, 0.040, 0.027, 0.028, 0.040, 0.027, 0.028, 0.040, 0.027, 0.028, 0.040, 0.027, 0.028, 0.040, 0.027, 0.028, 0	Zhang et al.,2008	17	767 🔶	0.022 (0.013, 0.035)	1.99
Zhang et al., 2010 149 1015 0.477 196 Lit et al., 2012 94 865 0.046 0.043, 0.054 2.017 Zhao et al., 2013 188 4045 0.039 0.033, 0.035, 0.045 2.017 Zhao et al., 2014 141 4988 0.096 0.0039 0.003, 0.003, 0.003, 0.045 2.01 Sun et al., 2014 142 3086 0.096 0.0039 0.003, 0.003, 0.003, 0.003, 0.045 2.01 Lue et al., 2014 142 3086 0.006 0.061 0.005 2.01 Vue et al., 2016 155 567 0.273 0.237 0.121 1.98 Cao et al., 2013 119 3660 0.066 0.012 0.016 0.012 0.016 0.012 0.016 0.012 0.016 0.012 0.016 0.012 0.016 0.012 0.016 0.012 0.016 0.012 0.016 0.012 0.016 0.012 0.016 0.012 0.016 0.012 0.016 0.012 0.016	Ge et al.,2009	237	7030 🔶	0.034 (0.030, 0.038)	2.01
Li et al2010 310 6447 0.048 (0.043, 0.054) 201 Jin et al2013 158 4045 0.039 (0.033, 0.045) 201 Jin et al2014 121 3085 0.039 (0.033, 0.047) 201 Jin et al2014 121 3085 0.048 (0.048, 0.055) 201 Liu et al2014 444 10919 0.051 (0.046, 0.055) 201 Liu et al2014 444 10919 0.041 (0.037, 0.042) 119 Cao et al2016 155 567 0.040 (0.028, 0.056) 159 Cao et al2018 322 200 0.166 (0.114, 0.124) 200 Cao et al2021 103 1036 0.099 (0.082, 0.119) 200 Cao et al2021 113 3650 0.037 (0.229, 0.322, 0.321 210 In et al2001 32 784 0.036 (0.032, 0.041) 201 Cao et al2023 119 3650 0.042 (0.003, 0.047) 201 In et al2004 175 678 0.037 (0.229, 0.322) 201 In et al2004 15 678 0.022 (0.012, 0.373) 201 V	Zhang et al.,2010	149	1015	0.147 (0.126, 0.170)	1.99
Jin et al.,2012 94 865 0.199 (0.089, 0.131) 158 Zhao et al.,2013 186 4945 0.039 (0.033, 0.045) 2.01 Sun et al.,2014 141 3085 0.039 (0.033, 0.047) 2.01 Hu et al.,2014 349 6842 0.051 (0.046, 0.055) 2.01 Hu et al.,2014 349 6842 0.051 (0.046, 0.055) 2.01 Hu et al.,2016 155 567 0.273 (0.237, 0.312) 188 Cao et al.,2018 286 1726 0.046 (0.028, 0.056) 2.01 Cao et al.,2018 286 1726 0.166 (0.148, 0.144) 2.00 Guo et al.,2020 103 1036 0.039 (0.028, 0.016) 2.01 Guo et al.,2020 13 3090 0.016 (0.028, 0.017) 190 In et al.,2002 47 3900 0.012 (0.009, 0.016) 2.01 SRDSG,2003 247 6826 0.036 (0.033, 0.047) 2.01 Up et al.,2004 176 678 0.036 (0.033, 0.047) 2.01 Vang et al.,2007 73 2000 0.036 (0.023, 0.040) 2.00 Co	Li et al.,2010	310	6447 🔶 🛛	0.048 (0.043, 0.054)	2.01
Hu et al.,2013 158 4045 0.039 (0.033, 0.045) 2.01 Sun et al.,2014 121 3085 0.039 (0.033, 0.047) 2.01 Hu et al.,2014 349 6842 0.051 (0.046, 0.056) 2.01 Lu et al.,2014 440 6842 0.051 (0.046, 0.056) 2.01 Lu et al.,2014 440 6842 0.041 (0.037, 0.045) 2.01 Vu et al.,2016 155 567 0.042 (0.028, 0.056) 1.98 Cao et al.,2018 32 200 0.160 (0.112, 0.218) 1.92 Cao et al.,2018 32 200 0.166 (0.114, 0.144) 2.00 Gue et al.,2020 103 1036 0.099 (0.082, 0.119) 2.00 Gue et al.,2020 127 47 3900 Strons et al. 0.041 (0.028, 0.057) 1.99 Lin et al.,2002 47 3900 Strons et al. 0.042 (0.025, 0.063) 1.99 Lin et al.,2003 54 1168 0.044 (0.028, 0.057) 1.99 Lin et al.,2004 175 678 0.042 (0.025, 0.037) 1.99 Van et al.,2007 131 6304	Jin et al.,2012	94	865 🔸	0.109 (0.089, 0.131)	1.99
Zhae tal.,2013 481 488 0.096 (0.088, 0.105) 2.01 Nun etal.,2014 149 6842 0.051 (0.046, 0.056) 2.01 Liu etal.,2014 444 10819 0.041 (0.037, 0.045) 2.01 Liu etal.,2014 444 10819 0.041 (0.037, 0.045) 1.95 Viu etal.,2015 33 819 0.040 (0.028, 0.056) 1.95 Viu etal.,2016 155 567 0.273 (0.237, 0.312) 1.15 Zhang etal.,2020 103 1036 0.090 (0.082, 0.119) 2.00 Guo etal.,2023 1119 3650 0.041 (0.028, 0.057) 1.98 Lin etal.,2001 32 784 0.041 (0.028, 0.057) 1.98 Lin etal.,2002 47 3800 0.046 (0.032, 0.041) 2.00 SRDSG,2003 247 6825 0.042 (0.094, 0.034, 0.047) 2.01 Lin etal.,2004 15 678 0.022 (0.012, 0.036) 2.00 Viang etal.,2004 15 678 0.036 (0.032, 0.041) 2.01 Lin etal.,2007 73 2000 0.021 (0.017, 0.025) 2.01	Hu et al.,2013	158	4045 🔶 🛛	0.039 (0.033, 0.045)	2.01
Sun et al.,2014 121 3085 0.039 (0.033, 0.047) 2.01 Liu et al.,2014 444 10819 0.051 (0.046, 0.056) 2.01 Ng et al.,2016 155 5567 0.027 (0.237, 0.312) 1.98 Cao et al.,2018 32 200 0.160 (0.12, 0.218) 1.92 Cao et al.,2018 32 200 0.160 (0.12, 0.218) 1.92 Cao et al.,2021 133 365 0.273 (0.237, 0.312) 1.98 Cao et al.,2023 113 3650 0.059 (0.082, 0.19) 2.00 Guo et al.,2023 113 3650 0.307 (0.227, 0.322) 2.01 In et al.,2001 32 784 0.051 (0.012, 0.064) 2.01 SURDS2,.2023 477 3900 3900 2.01 0.036 (0.032, 0.041) 2.01 Chard al.,2014 179 5728 0.035 (0.30, 0.040) 2.01 0.036 (0.032, 0.041) 2.01 Chard al.,2007 131 6304 0.022 (0.012, 0.036) 1.99 0.021 (0.017, 0.025) 2.01 Hu et al.,2007 131 6304 0.021 (0.017, 0.025) 2.01 0.036 (0.028,	Zhao et al.,2013	481	4988 🔶	0.096 (0.088, 0.105)	2.01
Hu et al.,2014 349 6842 0.051 (0.046, 0.056) 2.01 Ng et al.,2015 33 819 0.040 (0.028, 0.056) 1.96 Wu et al.,2016 155 567 0.273 (0.237, 0.312) 1.96 Zhang et al.,2018 220 0.166 (0.148, 0.184) 2.00 0.069 (0.028, 0.056) 1.95 Cao et al.,2013 126 1726 0.166 (0.148, 0.184) 2.00 0.099 (0.028, 0.19) 2.00 Guo et al.,2023 119 3650 0.037 (0.282, 0.057) 1.99 2.00 Guo et al.,2023 47 6826 0.014 (0.028, 0.057) 1.99 SRDSG,2003 247 6826 0.012 (0.009, 0.016) 2.01 SRDSG,2003 417 6816 0.046 (0.035, 0.060, 0.20 0.002 (0.012, 0.036) 1.99 Wang et al.,2004 15 678 0.035 (0.030, 0.040) 2.01 Wang et al.,2004 15 678 0.046 (0.035, 0.060, 0.20 0.002 (0.012, 0.036) 1.99 Wang et al.,2007 13 6304 0.046 (0.035, 0.060, 2.00 0.036 (0.032, 0.046) 2.01 Un et al.,2007 16 4020	Sun et al.,2014	121	3085 🔶	0.039 (0.033, 0.047)	2.01
Liu et al.,2014 4.44 10819 2 201 Ng et al.,2015 33 819 2 0.0404 (0.022, 0.066) 1.96 Cao et al.,2018 32 200 0.668 (0.142, 0.218) 1.92 Cao et al.,2020 103 1036 0.099 (0.082, 0.119) 2.00 Guo et al.,2020 103 1036 0.099 (0.082, 0.119) 2.00 Guo et al.,2021 119 3650 0.037 (0.292, 0.322) 2.01 (0.168 (0.144, 0.028, 0.067) 1.99 Lin et al.,2001 32 74 0.041 (0.028, 0.067) 1.99 Cao et al.,2023 1119 3650 0.037 (0.292, 0.322) 2.01 (0.410,028, 0.057) 1.99 Lin et al.,2001 32 764 0.037 (0.292, 0.322) 2.01 (0.410,028, 0.057) 1.99 Cao et al.,2023 119 3650 0.037 (0.292, 0.322) 2.01 (0.410,028, 0.057) 1.99 Cao et al.,2003 247 6826 0.0337 (0.292, 0.322) 2.01 (0.410,028, 0.057) 1.99 Cao et al.,2004 15 678 0.002 0.012 (0.038, 0.040) 2.01 Pot al.,2004 15 678 0.002 (0.012, 0.036) 0.20 (0.22 (0.017, 0.036) 0.022 (0.012, 0.036) 1.99 Cao et al.,2007 13 6304 0.002 (0.040 0.022) 0.021 Cao et al.,2007 13 6304 0.002 (0.033, 0.040) 2.01 Hou et al.,2007 13 6304 0.002 (0.033, 0.047) 2.01 Hou et al.,2007 13 2.00 0.01 Lin et al.,2009 246 1362 0.033 Cao et al.,2007 126 4020 0.033 (0.033, 0.030) 2.01 Cao et al.,2007 126 4020 0.033 (0.033, 0.047) 2.01 Lin et al.,2009 245 4286 0.033 (0.330, 0.306) 2.01 Cao et al.,2017 128 4020 0.033 (0.033, 0.030) 2.01 Lin et al.,2009 39 9198 0.0133 (0.044, 0.125) 1.99 Che et al.,2014 93 9198 0.0133 (0.034, 0.125) 1.99 Wei et al.,2014 94 1689 0.059 (0.054, 0.064) 2.00 Che et al.,2014 94 1689 0.059 (0.045, 0.051) 1.99 Che et al.,2014 94 1689 0.056 (0.045, 0.068) 2.00 Che et al.,2014 94 1689 0.056 (0.045, 0.068) 2.00 Che et al.,2014 94 1689 0.022 (0.017, 0.059, 0.037) 2.01 Hu et al.,2016 304 934 0.022 (0.027, 0.036) 2.00 Che et al.,2014 94 1689 0.026 (0.037, 0.059) 0.000 Che et al.,2014 74 75 0.026 0.027 (0.027, 0.027) 0.026 (0.037, 0.027) 0.026 (0.037, 0.026) 0.037 (0.026, 0.037)	Hu et al.,2014	349	6842 🔶	0.051 (0.046, 0.056)	2.01
Ng et al.,2015 33 819 0.040 (0.028, 0.056) 1.95 Wu et al.,2016 155 567 0.273 (0.237, 0.312) 1.98 Can et al.,2018 226 0.166 (0.112, 0.218) 1.92 Zhang et al.,2021 103 1036 0.099 (0.082, 0.056) 1.92 Guo et al.,2023 1119 3650 0.099 (0.082, 0.019) 2.00 Guo et al.,2023 1119 3650 0.037 (0.292, 0.322) 2.01 In et al.,2002 47 3900 0.012 (0.009, 0.016) 2.01 SRDSG.,2003 247 6826 0.044 (0.035, 0.060) 2.00 SRDSG.,2003 247 6826 0.046 (0.035, 0.041) 2.01 Wang et al.,2004 15 678 0.035 (0.030, 0.041) 2.01 Hou et al.,2007 13 636 0.042 (0.034, 0.047) 2.01 Hou et al.,2007 73 2.00 0.036 (0.029, 0.036) 2.00 Zou et al.,2007 73 2.00 0.036 (0.029, 0.036) 2.01 Huang et al.,2017 73 2.00 0.036 (0.020, 0.037) 2.01 Lin et al.,2010	Liu et al.,2014	444	10819 🔶	0.041 (0.037, 0.045)	2.01
Wu et al., 2016 155 567 0.273 (0.237, 0.312) 1.98 Cao et al., 2018 32 200 0.166 (0.114, 0.218) 1.92 Lang et al., 2018 286 1726 0.166 (0.114, 0.184) 1.92 Cao et al., 2020 103 1036 0.039 (0.082, 0.119) 2.00 Guo et al., 2023 1119 3650 0.037 (0.292, 0.322) 2.01 Ip et al., 2001 32 784 0.041 (0.028, 0.057) 1.96 Lin et al., 2002 47 3900 0.012 (0.009, 0.016) 2.01 Zhang et al., 2004 15 678 0.044 (0.038, 0.067) 1.96 Wang et al., 2004 179 5128 0.035 (0.030, 0.040) 2.01 Hou et al., 2004 179 5128 0.035 (0.030, 0.040) 2.01 Hou et al., 2007 73 2000 0.036 (0.029, 0.046) 2.00 Zou et al., 2007 73 2000 0.036 (0.030, 0.036) 2.01 Lin et al., 2007 73 2000 0.036 (0.030, 0.036) 2.01 Lin et al., 2007 73 2000 0.036 (0.030, 0.036) 2.01	Ng et al.,2015	33	819 🔶	0.040 (0.028, 0.056)	1.99
Cao et al., 2018 32 200 0.160 0.112, 0.218) 1.92 Zhang et al., 2018 286 1726 0.166 0.148, 0.184, 0.184 200 Guo et al., 2021 103 1035 0.367 0.282, 0.322 2.01 Ip et al., 2001 32 784 0.041 (0.028, 0.057) 1.96 In et al., 2002 47 3800 0.041 (0.028, 0.057) 1.96 SRDSG, 2003 247 6826 0.038 (0.032, 0.041) 2.01 Jang et al., 2004 15 678 0.022 (0.012, 0.036) 1.99 Wang et al., 2004 15 678 0.022 (0.012, 0.036) 1.99 Wang et al., 2004 15 678 0.022 (0.012, 0.036) 1.99 Wang et al., 2007 131 6304 0.021 (0.017, 0.025) 2.01 Gong et al., 2007 136 364 0.021 (0.017, 0.025) 2.01 Hu et al., 2007 136 364 0.036 (0.029, 0.046) 2.00 Cuo et al., 2017 126 4020 0.036 (0.029, 0.046) 2.00 Lin et al., 2010 325 2.018 0.046 (0.042	Wu et al.,2016	155	567	0.273 (0.237, 0.312)	1.98
Zhang et al., 2018 286 1726 0.166 (0.148, 0.184) 2.00 Hong et al., 2020 103 1036 0.099 (0.082, 0.119) 2.00 Guo et al., 2021 1119 3650 0.099 (0.082, 0.119) 2.00 Lin et al., 2001 32 784 0.011 (0.028, 0.057) 1.58 Lin et al., 2003 247 6826 0.012 (0.009, 0.016) 2.01 Zhang et al., 2004 15 678 0.022 (0.012, 0.036) 1.99 Wang et al., 2004 179 5128 0.035 (0.030, 0.040) 2.01 Hou et al., 2007 131 6304 0.046 (0.032, 0.046) 2.00 You et al., 2007 131 6304 0.021 (0.017, 0.025) 2.01 Cou et al., 2007 73 2000 0.033 (0.030, 0.036) 2.01 Huag et al., 2009 446 13625 0.033 (0.030, 0.036) 2.01 Huag et al., 2019 255 2.018 0.033 (0.030, 0.036) 2.01 Huag et al., 2010 255 2.018 0.048 (0.042, 0.055) 2.01 Huag et al., 2016 39 9.04 0.048 (0.042, 0.055) 2	Cao et al2018	32	200	0.160 (0.112, 0.218)	1.92
Hong et al., 2020 10.3 10.36 0.099 (0.082, 0.118) 2.00 Guo et al., 2023 1119 3650 0.307 (0.292, 0.322) 2.01 Lin et al., 2001 32 784 0.041 (0.028, 0.017) 1.98 Lin et al., 2002 47 3900 0.012 (0.009, 0.016) 2.01 SRDSG, 2003 247 6826 0.036 (0.032, 0.041) 2.01 Janag et al., 2004 15 678 0.022 (0.012, 0.036) 1.49 Wang et al., 2004 15 678 0.022 (0.012, 0.036) 1.99 Wang et al., 2006 146 3616 0.040 (0.034, 0.047) 2.01 Hu et al., 2007 13 6304 0.021 (0.017, 0.025) 2.01 Goog et al., 2007 126 4020 0.033 (0.030, 0.036) 2.01 Huang et al., 2009 246 13625 0.033 (0.030, 0.036) 2.01 Hu et al., 2010 325 2018 0.034 (0.042, 0.055) 2.01 Ma et al., 2010 325 218 0.048 (0.42, 0.055) 2.01 Ma et al., 2010 54 266 0.056 (0.044, 0.055) 2.01 <td>Zhang et al. 2018</td> <td>286</td> <td>1726</td> <td>0.166 (0.148, 0.184)</td> <td>2.00</td>	Zhang et al. 2018	286	1726	0.166 (0.148, 0.184)	2.00
Gue et al., 2023 1119 3650 0.0307 (0.292, 0.322, 0.212) 2.01 In et al., 2001 32 784 0.041 (0.028, 0.067) 1.98 SRDSG, 2003 247 6826 0.036 (0.032, 0.041) 2.01 SRDSG, 2003 247 6826 0.036 (0.032, 0.041) 2.01 Je et al., 2004 15 678 0.022 (0.012, 0.036) 1.99 Wang et al., 2004 15 678 0.035 (0.030, 0.040) 2.01 Hou et al., 2006 146 3616 0.022 (0.012, 0.036) 0.021 (0.017, 0.025) 2.01 Gong et al., 2007 73 2000 0.036 (0.029, 0.046) 2.00 0.031 (0.026, 0.037) 2.01 Hua et al., 2009 426 0.035 (0.030, 0.030) 2.01 0.033 (0.030, 0.036) 2.01 In et al., 2010 325 2.018 0.013 (0.026, 0.046) 2.00 Ma et al., 2010 325 2.018 0.013 (0.026, 0.027) 2.01 Uin et al., 2011 325 0.024 0.035 (0.046) 2.01 Che et al., 2011 325 0.013 (0.026, 0.027) 0.00 0.013 (0.028, 0.125) 1.99<	Hong et al. 2020	103	1036	0.099 (0.082 0.119)	2.00
Lin et al., 2001 32 784 0.041 (0.028, 0.022) 2.01 Lin et al., 2002 47 3900 0.0112 (0.009, 0.016) 2.01 SRDSG, 2003 247 6826 0.036 (0.032, 0.041) 2.01 Zhang et al., 2003 54 1168 0.046 (0.035, 0.060) 2.00 Yang et al., 2004 179 5128 0.035 (0.030, 0.04) 2.01 Hou et al., 2004 179 5128 0.035 (0.030, 0.04) 2.01 Hu et al., 2007 131 6304 0.040 (0.034, 0.047) 2.01 Gong et al., 2007 126 4020 0.033 (0.022, 0.045) 2.01 Huang et al., 2009 446 13625 0.033 (0.026, 0.037) 2.00 Lin et al., 2009 426 0.033 (0.026, 0.037) 2.01 Huang et al., 2019 325 2.018 0.033 (0.030, 0.036) 2.01 In et al., 2019 325 2.018 0.046 (0.042, 0.055) 2.011 In et al., 2010 543 9198 0.059 (0.054, 0.064) 2.011 Che et al., 2014 96 1326 0.072 (0.059, 0.088) 2.00	Guo et al. 2023	1119	3650	0.307 (0.292, 0.322)	2.01
Junct 1, 2002 47 300 0.012 (0.003, 0.016) 2.01 SRDSG, 2003 247 6826 0.036 (0.032, 0.041) 2.01 Zhang et al, 2003 54 1168 0.046 (0.035, 0.060) 2.00 Wang et al, 2004 15 678 0.022 (0.012, 0.036) 1.98 Wang et al, 2004 179 5128 0.033 (0.030, 0.040) 2.01 Hou et al, 2007 131 6304 0.040 (0.034, 0.047) 2.01 Gong et al, 2007 131 6304 0.021 (0.017, 0.025) 2.01 Hu et al, 2007 132 0.030 0.031 (0.028, 0.037) 2.00 Cou et al, 2009 446 13625 0.033 (0.030, 0.036) 2.01 Hu at al, 2009 205 4286 0.044 (0.042, 0.055) 2.01 Ma et al, 2010 93 904 0.103 (0.084, 0.125) 1.99 Wei et al, 2013 42 335 0.125 (0.092, 0.166) 1.96 Peng et al, 2014 96 1326 0.040 (0.033, 0.050) 2.00 June et al, 2014 96 1326 0.077 (0.025, 0.088) 2.00	In et al 2001	32	784	0.007 (0.202, 0.022)	1 99
Lin tai, 2002 47 6826 0.036 (0.032, 0.041) 2.01 Zhang et al, 2003 54 1168 0.046 (0.035, 0.060) 2.00 Ip et al, 2004 15 678 0.052 (0.012, 0.036) 1.90 Wang et al, 2004 15 678 0.052 (0.012, 0.036) 1.90 Wang et al, 2004 179 5128 0.035 (0.032, 0.040) 2.01 Hu et al, 2007 131 6304 0.021 (0.017, 0.025) 2.01 Gong et al, 2007 126 4020 0.031 (0.028, 0.040) 2.00 Zou et al, 2007 126 4020 0.031 (0.028, 0.037) 2.01 Hu at al, 2009 246 13625 0.043 (0.024, 0.055) 2.01 Ma et al, 2010 325 2018 0.031 (0.028, 0.041) 2.00 Lin et al, 2010 325 2018 0.046 (0.042, 0.055) 2.01 Ma et al, 2010 325 2018 0.059 (0.54, 0.064) 2.00 Lin et al, 2010 33 914 0.059 (0.54, 0.064) 2.01 Che et al, 2011 272 6824 0.040 (0.035, 0.056) 2.00	Linetal 2002	17			2.01
On DOD, 2003 247 Odd2 0.047 2.017 2.01 Zhang et al., 2004 15 678 0.022 (0.012, 0.036) 1.95 Wang et al., 2004 179 5128 0.035 (0.030, 0.040) 2.01 Hou et al., 2006 146 3616 0.042 (0.034, 0.047) 2.01 Hu et al., 2007 131 6304 0.021 (0.017, 0.025) 2.01 Gong et al., 2007 126 4020 0.031 (0.026, 0.037) 2.01 June et al., 2009 446 13625 0.033 (0.030, 0.036) 2.01 Lin et al., 2010 325 4286 0.048 (0.042, 0.055) 2.01 Ma et al., 2010 343 9198 0.013 (0.084, 0.125) 1.99 Wei et al., 2010 543 9198 0.059 (0.054, 0.064) 2.01 Che et al., 2011 272 6824 0.046 (0.035, 0.068) 2.00 Che et al., 2014 96 1326 0.072 (0.059, 0.088) 2.00 Che et al., 2014 96 1326 0.073 (0.038, 0.050) 2.00 Un et al., 2014 94 1689 0.056 (0.045, 0.068) 2.00	SPDSC 2003	247	6826	0.012 (0.003, 0.010)	2.01
Zhang et al., 2005 34 1100 0.040 (0.055, 0.000) 2.00 Wang et al., 2004 179 5128 0.035 (0.030, 0.040) 2.01 Hou et al., 2006 146 3616 0.040 (0.034, 0.047) 2.01 Gong et al., 2007 131 6304 0.021 (0.017, 0.025) 2.01 Gong et al., 2007 73 2000 0.031 (0.026, 0.037) 2.01 Lin et al., 2009 446 13625 0.033 (0.040) 2.01 Lin et al., 2009 446 13625 0.033 (0.030, 0.036) 2.02 Lin et al., 2010 325 2018 0.048 (0.042, 0.055) 2.01 Ma et al., 2010 325 2018 0.161 (0.145, 0.178) 2.00 Lin et al., 2011 543 9198 0.059 (0.054, 0.264) 2.01 Vei et al., 2011 543 9198 0.059 (0.058, 0.200) 2.00 Zheng et al., 2014 96 1326 0.046 (0.035, 0.046) 2.01 Che et al., 2014 94 1689 0.056 (0.045, 0.068) 2.00 Oki et al., 2016 304 934 0.025 (0.057, 0.168) 1.96	Zhang at al. 2002	247 54		0.030 (0.032, 0.041)	2.01
Ip et al.,2004 15 676 0.022 (0.012, 0.036) 1.98 Wang et al.,2006 146 3616 0.036 (0.020, 0.040) 2.01 Hou et al.,2007 131 6304 0.021 (0.017, 0.025) 2.01 Gong et al.,2007 136 60.029, 0.046) 2.00 0.033 (0.029, 0.046) 2.00 Cou et al.,2007 126 4020 0.033 (0.026, 0.037) 2.01 Hung et al.,2009 446 13625 0.033 (0.030, 0.036) 2.01 Lin et al.,2010 93 904 0.161 (0.145, 0.178) 2.00 Lin et al.,2010 93 904 0.103 (0.084, 0.125) 1.99 Wei et al.,2011 272 6824 0.046 (0.035, 0.064) 2.01 Che et al.,2014 96 1326 0.072 (0.059, 0.088) 2.00 Vue et al.,2014 96 1326 0.072 (0.059, 0.088) 2.00 Jin et al.,2014 96 1326 0.073 (0.058, 0.090) 2.00 Jin et al.,2016 82 1126 0.073 (0.058, 0.090) 2.00 Jin et al.,2017 68 2508 0.027 (0.021, 0.034) 2	Zhang et al.,2003	15		0.040 (0.033, 0.000)	2.00
Ward get al., 2006 146 3616 0.0430 0.040) 2.01 Hu et al., 2007 131 6304 0.021 (0.017, 0.025) 2.01 Gong et al., 2007 73 2000 0.036 (0.029, 0.046) 2.00 Zou et al., 2007 126 4020 0.033 (0.020, 0.037) 2.01 Huang et al., 2009 446 13625 0.033 (0.020, 0.035) 2.01 Lin et al., 2010 325 2018 0.048 (0.042, 0.055) 2.01 Lin et al., 2010 325 2018 0.161 (0.145, 0.178) 2.00 Lin et al., 2010 343 9198 0.059 (0.054, 0.064) 2.01 Che et al., 2011 272 6824 0.040 (0.035, 0.045) 2.01 Zheng et al., 2014 94 1869 0.056 (0.045, 0.068) 2.00 Wu et al., 2014 94 1869 0.056 (0.045, 0.068) 2.00 Wu et al., 2014 94 1869 0.027 (0.059, 0.088) 2.00 Vu et al., 2014 94 1869 0.027 (0.021, 0.034) 2.01 Zheng et al., 2017 118 3780 0.027 (0.022, 0.357) 1	Ip et al.,2004	15		0.022 (0.012, 0.036)	1.99
Hou et al., 2006 146 36 16 0.040 (0.034, 0.047) 2.01 Gong et al., 2007 131 6304 0.021 (0.017, 0.025) 2.01 Gong et al., 2007 126 4020 0.036 (0.029, 0.046) 2.00 Zou et al., 2009 246 13625 0.033 (0.030, 0.036) 2.01 Huang et al., 2010 325 2018 0.048 (0.042, 0.055) 2.01 Ma et al., 2010 325 2018 0.161 (0.145, 0.178) 2.00 Lin et al., 2010 33 904 0.035 (0.064) 2.01 Vei et al., 2011 272 6824 0.046 (0.042, 0.055) 2.01 Che et al., 2011 272 6824 0.059 (0.054, 0.064) 2.01 Zheng et al., 2013 42 335 0.125 (0.092, 0.166) 1.96 Peng et al., 2014 96 1326 0.072 (0.021, 0.034) 2.00 Vu et al., 2014 94 1689 0.072 (0.021, 0.034) 2.00 Jin et al., 2014 94 1689 0.072 (0.021, 0.034) 2.00 Ju et al., 2014 94 1689 0.073 (0.058, 0.090) 2.00 <td>Wang et al.,2004</td> <td>1/9</td> <td></td> <td>0.030 (0.030, 0.040)</td> <td>2.01</td>	Wang et al.,2004	1/9		0.030 (0.030, 0.040)	2.01
Hu et al., 2007 131 6304 0.021 (0.017, 0.025) 2.01 Gong et al., 2007 126 4020 0.036 (0.029, 0.046) 2.00 Lin et al., 2009 446 13625 0.033 (0.030, 0.036) 2.01 Lin et al., 2010 325 2018 0.048 (0.042, 0.055) 2.01 Ma et al., 2010 325 2018 0.161 (0.145, 0.178) 2.00 Lin et al., 2010 543 9198 0.049 (0.035, 0.045) 2.01 Vei et al., 2011 272 6824 0.048 (0.042, 0.055) 2.01 Zheng et al., 2013 42 335 0.059 (0.054, 0.064) 2.01 Zheng et al., 2014 96 1326 0.049 (0.033, 0.050) 2.00 Che et al., 2014 94 1689 0.072 (0.059, 0.088) 2.00 Vu et al., 2014 96 1326 0.040 (0.033, 0.050) 2.00 Su et al., 2014 94 1689 0.027 (0.059, 0.088) 2.00 Jin et al., 2016 304 934 0.027 (0.021, 0.034) 2.01 Jang et al., 2017 68 2508 0.027 (0.021, 0.034) 2.01	Hou et al.,2006	146		0.040 (0.034, 0.047)	2.01
Gong et al.,2007 73 2000 0.036 (0.029, 0.046) 2.00 Zou et al.,2007 126 4020 0.031 (0.026, 0.037) 2.01 Huang et al.,2009 205 4286 0.033 (0.030, 0.036) 2.01 Lin et al.,2010 325 2018 0.161 (0.145, 0.178) 2.00 Lin et al.,2010 33 904 0.033 (0.026, 0.037) 2.01 Vei et al.,2011 272 6824 0.059 (0.054, 0.064) 2.01 Che et al.,2011 272 6824 0.059 (0.054, 0.064) 2.01 Zheng et al.,2014 96 1326 0.052 (0.092, 0.166) 1.96 Peng et al.,2014 96 1326 0.072 (0.059, 0.088) 2.00 Wu et al.,2014 94 1689 0.072 (0.059, 0.088) 2.00 Vu et al.,2014 62 1566 0.073 (0.058, 0.090) 2.00 Su et al.,2016 304 934 0.325 (0.295, 0.357) 1.99 Ma et al.,2017 68 2508 0.027 (0.021, 0.034) 2.01 Zhang et al.,2017 118 3780 0.027 (0.024, 0.037) 2.01	Hu et al.,2007	131	6304	0.021 (0.017, 0.025)	2.01
Zou et al., 2007 126 4020 0.031 (0.026, 0.037) 2.01 Huang et al., 2009 446 13625 0.033 (0.030, 0.036) 2.01 Ma et al., 2010 325 2018 0.048 (0.042, 0.055) 2.01 Lin et al., 2010 325 2018 0.161 (0.145, 0.178) 2.00 Vei et al., 2010 543 9198 0.059 (0.054, 0.064) 2.01 Che et al., 2011 272 6824 0.040 (0.035, 0.045) 2.01 Zheng et al., 2013 42 335 0.125 (0.092, 0.166) 1.96 Peng et al., 2014 96 1326 0.072 (0.059, 0.088) 2.00 Un et al., 2014 96 1326 0.073 (0.050, 0.069) 2.00 Su et al., 2014 96 1326 0.073 (0.050, 0.068) 2.00 Un et al., 2014 92 1566 0.073 (0.058, 0.068) 2.00 Su et al., 2016 304 934 0.025 (0.037) 1.99 Ma et al., 2016 304 934 0.027 (0.021, 0.034) 2.01 Lin et al., 2018 174 1760 0.099 (0.085, 0.114) 2.00 <	Gong et al.,2007	/3	2000	0.036 (0.029, 0.046)	2.00
Huang et al., 2009 446 13625 0.033 (0.030, 0.036) 2.01 Lin et al., 2010 325 2018 0.048 (0.042, 0.055) 2.01 Ma et al., 2010 325 2018 0.161 (0.145, 0.178) 2.00 Wei et al., 2010 543 9198 0.059 (0.054, 0.064) 2.01 Che et al., 2011 272 6824 0.040 (0.035, 0.045) 2.01 Zheng et al., 2013 42 335 0.125 (0.092, 0.166) 1.96 Peng et al., 2014 96 1326 0.056 (0.045, 0.068) 2.00 Wu et al., 2014 94 1689 0.056 (0.045, 0.068) 2.00 Vu et al., 2014 62 1566 0.072 (0.059, 0.088) 2.00 Jin et al., 2016 82 1126 0.073 (0.058, 0.090) 2.00 Jin et al., 2016 82 1126 0.031 (0.026, 0.037) 1.99 Ma et al., 2017 68 2508 0.027 (0.021, 0.034) 2.01 Zhang et al., 2018 174 1760 0.031 (0.026, 0.037) 2.00 Deng et al., 2018 518 1961 0.0264 (0.245, 0.284) 2.00	Zou et al.,2007	126	4020	0.031 (0.026, 0.037)	2.01
Lin et al.,2009 205 4286 0.048 (0.042, 0.055) 2.01 Ma et al.,2010 325 2018 0.103 (0.084, 0.125) 1.99 Wei et al.,2010 543 9198 0.059 (0.054, 0.064) 2.01 Che et al.,2011 272 6824 0.0125 (0.059, 0.059) 2.00 Chen et al.,2013 42 335 0.045 2.01 Chen et al.,2014 96 1326 0.072 (0.059, 0.088) 2.00 Chen et al.,2014 94 1689 0.056 (0.045, 0.068) 2.00 Wu et al.,2014 62 1566 0.0072 (0.059, 0.088) 2.00 Jin et al.,2016 82 1126 0.073 (0.058, 0.090) 2.00 Su et al.,2017 68 2508 0.0073 (0.058, 0.090) 2.00 Su et al.,2017 118 3780 0.0073 (0.058, 0.090) 2.00 Deng et al.,2018 518 1961 0.031 (0.026, 0.037) 2.01 Hu et al.,2018 518 1961 0.031 (0.026, 0.037) 2.01 Zhang et al.,2019 78 1903 0.0073 (0.058, 0.090) 2.00 Su et al.,2024 64 1408 0.044 0.035 (0.045) 2.00 Out et al.,2024 64 1408 0.044 0.025 (0.035) 2.00 Out et al.,2024 1019 1155 0.008 0.0073 (0.058, 0.090) 2.00 Out et al.,2024 1019 1155 0.008 0.0073 (0.058, 0.090) 2.00 Out et al.,2024 1019 1155 0.008 0.0073 (0.058, 0.059) 2.00 Out et al.,2024 1019 1155 0.008 0.0073 (0.050 0.200 Out et al.,2024 1019 1155 0.008 0.0073 (0.050 0.200 Out et al.,2024 1019 1155 0.008 0.005 0.008 0.0073 (0.035, 0.058) 2.000 Out et al.,2024 1019 1155 0.008 0.0057 (0.042, 0.075) 1.99 Out et al.,2024 1019 1155 0.008 0.0073 0.005 0.008 0.0073 (0.058, 0.013) 100.	Huang et al.,2009	446	13625 🔶	0.033 (0.030, 0.036)	2.01
Ma et al.,2010 325 2018 0.161 (0.145, 0.178) 2.00 Lin et al.,2010 93 904 0.103 (0.084, 0.125) 1.99 Wei et al.,2010 543 9198 0.059 (0.054, 0.064) 2.01 Che et al.,2011 272 6824 0.040 (0.035, 0.045) 2.01 Zheng et al.,2013 42 335 0.125 (0.092, 0.166) 1.96 Peng et al.,2014 96 1326 0.072 (0.059, 0.088) 2.00 Chen et al.,2014 94 1689 0.056 (0.045, 0.068) 2.00 Vu et al.,2014 62 1566 0.073 (0.058, 0.090) 2.00 Jin et al.,2016 82 1126 0.032 (0.295, 0.357) 1.99 Ma et al.,2017 18 3780 0.027 (0.021, 0.034) 2.01 Zhang et al.,2017 118 3780 0.031 (0.266, 0.037) 2.01 Hu et al.,2018 174 1760 0.099 (0.085, 0.114) 2.00 Deng et al.,2019 78 1903 0.057 (0.042, 0.075) 1.99 Liu et al.,2024 64 1408 0.057 (0.042, 0.075) 1.99	Lin et al.,2009	205	4286	0.048 (0.042, 0.055)	2.01
Lin et al.,2010 93 904 0.103 (0.084, 0.125) 1.98 Wei et al.,2010 543 9198 0.059 (0.054, 0.064) 2.01 Che et al.,2011 272 6824 0.040 (0.035, 0.045) 2.01 Zheng et al.,2013 42 335 0.125 (0.092, 0.166) 1.96 Peng et al.,2014 96 1326 0.072 (0.059, 0.068) 2.00 Chen et al.,2014 94 1689 0.056 (0.045, 0.068) 2.00 Wu et al.,2016 82 126 0.073 (0.058, 0.090) 2.00 Jin et al.,2016 82 126 0.073 (0.058, 0.090) 2.00 Su et al.,2017 68 2508 0.073 (0.058, 0.090) 2.00 Su et al.,2017 18 3780 0.027 (0.021, 0.034) 2.01 Hu et al.,2018 174 1760 0.099 (0.085, 0.114) 2.00 Deng et al.,2019 78 1903 0.041 (0.033, 0.051) 2.00 Sun et al.,2024 64 1408 0.057 (0.042, 0.075) 1.99 Liu et al.,2024 64 1408 0.045 (0.063, 0.113) 0.005 <	Ma et al.,2010	325	2018 🔶	0.161 (0.145, 0.178)	2.00
Wei et al.,2010 543 9198 0.059 (0.054, 0.064) 2.01 Che et al.,2011 272 6824 0.040 (0.035, 0.045) 2.01 Zheng et al.,2013 42 35 0.125 (0.092, 0.166) 1.96 Peng et al.,2014 96 1326 0.072 (0.059, 0.088) 2.00 Chen et al.,2014 94 1689 0.056 (0.045, 0.068) 2.00 Wu et al.,2014 62 1566 0.040 (0.030, 0.050) 2.00 Su et al.,2016 304 934 0.027 (0.029, 0.036) 2.00 Su et al.,2017 68 2508 0.072 (0.029, 0.037) 1.99 Ma et al.,2017 118 3780 0.027 (0.021, 0.034) 2.01 Zhang et al.,2017 118 3780 0.027 (0.024, 0.037) 2.01 Ue et al.,2018 518 1961 0.031 (0.026, 0.037) 2.01 Zhang et al.,2019 78 1903 0.057 (0.042, 0.075) 1.99 Out et al.,2023 46 808 0.057 (0.042, 0.075) 1.99 Sun et al.,2024 1019 1155 0.882 (0.862, 0.900) 2.00	Lin et al.,2010	93	904 🔶	0.103 (0.084, 0.125)	1.99
Che et al.,2011 272 6824 0.040 (0.035, 0.045) 2.01 Zheng et al.,2013 42 335 0.125 (0.092, 0.166) 1.96 Peng et al.,2014 96 1326 0.072 (0.059, 0.088) 2.00 Chen et al.,2014 94 1689 0.056 (0.045, 0.068) 2.00 Wu et al.,2014 62 1566 0.073 (0.058, 0.090) 2.00 Jin et al.,2016 82 1126 0.032 (0.058, 0.090) 2.00 Su et al.,2017 68 2508 0.027 (0.021, 0.034) 2.01 Zhang et al.,2017 118 3780 0.027 (0.021, 0.034) 2.01 Uu et al.,2018 518 1961 0.031 (0.026, 0.037) 2.01 Deng et al.,2019 78 1903 0.057 (0.042, 0.075) 1.99 Sun et al.,2024 64 1408 0.057 (0.042, 0.075) 1.99 Liu et al.,2024 64 1408 0.057 (0.042, 0.075) 1.99 Overall (h² = 99.700%, p = 0.00) 0.056 0.058 2.000	Wei et al.,2010	543	9198 🔶	0.059 (0.054, 0.064)	2.01
Zheng et al.,2013 42 335 0.125 (0.092, 0.166) 1.96 Peng et al.,2014 96 1326 0.072 (0.059, 0.088) 2.00 Chen et al.,2014 94 1689 0.056 (0.045, 0.068) 2.00 Wu et al.,2014 62 1566 0.073 (0.058, 0.090) 2.00 Jin et al.,2016 82 1126 0.073 (0.058, 0.090) 2.00 Su et al.,2017 68 2508 0.027 (0.021, 0.034) 2.01 Zhang et al.,2017 118 3780 0.031 (0.026, 0.037) 2.01 Hu et al.,2018 174 1760 0.099 (0.085, 0.114) 2.00 Sun et al.,2019 78 1903 0.057 (0.042, 0.075) 1.99 Liu et al.,2024 64 1408 0.057 (0.042, 0.075) 1.99 Liu et al.,2024 1019 1155 0.086 (0.063, 0.113) 0.0086 (0.063, 0.113) 100. Overall (h² = 99.700%, p = 0.00) Image tal. 0.086 (0.063, 0.113) 100.	Che et al.,2011	272	6824 🔶	0.040 (0.035, 0.045)	2.01
Peng et al.,2014 96 1326 0.072 (0.059, 0.088) 2.00 Chen et al.,2014 94 1689 0.056 (0.045, 0.068) 2.00 Wu et al.,2014 62 156 0.040 (0.030, 0.050) 2.00 Jin et al.,2016 82 1126 0.073 (0.058, 0.090) 2.00 Su et al.,2016 304 934 0.325 (0.295, 0.357) 1.99 Ma et al.,2017 18 3780 0.031 (0.026, 0.037) 2.01 Zhang et al.,2017 118 3780 0.031 (0.026, 0.037) 2.01 Hu et al.,2018 174 1760 0.099 (0.085, 0.114) 2.00 Deng et al.,2018 518 1961 0.027 (0.042, 0.075) 1.99 Liu et al.,2019 78 1903 0.041 (0.033, 0.051) 2.00 Sun et al.,2024 64 1408 0.057 (0.042, 0.075) 1.99 Liu et al.,2024 64 1408 0.057 (0.042, 0.075) 1.99 Overall (h² = 99.700%, p = 0.00) 0.086 (0.063, 0.113) 100.	Zheng et al.,2013	42	335	0.125 (0.092, 0.166)	1.96
Chen et al.,2014 94 1689 0.056 (0.045, 0.068) 2.00 Wu et al.,2014 62 1566 0.040 (0.030, 0.050) 2.00 Jin et al.,2016 304 934 0.0325 (0.295, 0.357) 1.99 Ma et al.,2017 68 2508 0.027 (0.021, 0.034) 2.01 Hu et al.,2018 174 1760 0.039 (0.085, 0.114) 2.00 Deng et al.,2018 518 1961 0.0264 (0.245, 0.284) 2.00 Zhang et al.,2019 78 1903 0.057 (0.042, 0.075) 1.99 Liu et al.,2024 64 1408 0.057 (0.042, 0.075) 1.99 Liu et al.,2024 1019 115 0.057 (0.042, 0.075) 1.99 Overall (h² = 99.700%, p = 0.00) Image tal.,2017 1019 0.086 (0.063, 0.113) 100.	Peng et al.,2014	96	1326 🔶	0.072 (0.059, 0.088)	2.00
Wu et al.,2014 62 1566 0.040 (0.030, 0.050) 2.00 Jin et al.,2016 82 1126 0.073 (0.058, 0.090) 2.00 Su et al.,2016 304 934 0.325 (0.295, 0.357) 1.99 Ma et al.,2017 68 2508 0.027 (0.021, 0.034) 2.01 Zhang et al.,2017 118 3780 0.031 (0.026, 0.037) 2.01 Hu et al.,2018 174 1760 0.099 (0.085, 0.114) 2.00 Deng et al.,2018 518 1961 0.024 (0.245, 0.284) 2.00 Zhang et al.,2019 78 1903 0.041 (0.033, 0.051) 2.00 Sun et al.,2023 46 808 0.057 (0.042, 0.075) 1.90 Liu et al.,2024 64 1408 0.086 (0.063, 0.113) 0.00 Overall (h² = 99.700%, p = 0.00) Image te al.,2024 0.086 (0.063, 0.113) 100.	Chen et al.,2014	94	1689 🔶 🛛	0.056 (0.045, 0.068)	2.00
Jin et al.,2016 82 1126 0.073 (0.058, 0.090) 2.00 Su et al.,2016 304 934 0.325 (0.295, 0.357) 1.99 Ma et al.,2017 68 2508 0.027 (0.021, 0.034) 2.01 Zhang et al.,2017 118 3780 0.031 (0.026, 0.037) 2.01 Hu et al.,2018 174 1760 0.099 (0.085, 0.114) 2.00 Deng et al.,2018 518 1961 0.264 (0.245, 0.284) 2.00 Zhang et al.,2019 78 1903 0.041 (0.033, 0.051) 2.00 Sun et al.,2023 46 808 0.057 (0.042, 0.075) 1.90 Liu et al.,2024 64 1408 0.086 (0.065, 0.113) 2.00 Overall (l^2 = 99.700%, p = 0.00) Image tel.,2024 0.086 (0.063, 0.113) 100.	Wu et al.,2014	62	1566 🔶 🛛	0.040 (0.030, 0.050)	2.00
Su et al.,2016 304 934 ● Ma et al.,2017 68 2508 0.027 (0.021, 0.034) 2.01 Zhang et al.,2017 118 3780 ● 0.031 (0.026, 0.037) 2.01 Hu et al.,2018 174 1760 0.099 (0.085, 0.114) 2.00 Deng et al.,2018 518 1961 ● 0.024 (0.245, 0.284) 2.00 Zhang et al.,2019 78 1903 ● 0.041 (0.033, 0.051) 2.00 Sun et al.,2023 46 808 ● 0.057 (0.042, 0.075) 1.99 Liu et al.,2024 1019 1155 ● 0.088 (0.063, 0.058) 2.00 Overall (h² = 99.700%, p = 0.00) ● ● 0.086 (0.063, 0.113) 100.	Jin et al.,2016	82	1126 🔶	0.073 (0.058, 0.090)	2.00
Ma et al.,2017 68 2508 0.027 (0.021, 0.034) 2.01 Zhang et al.,2017 118 3780 0.031 (0.026, 0.037) 2.01 Hu et al.,2018 174 1760 0.099 (0.085, 0.114) 2.00 Deng et al.,2018 518 1961 0.264 (0.245, 0.284) 2.00 Zhang et al.,2019 78 1903 0.057 (0.042, 0.075) 1.99 Liu et al.,2024 64 1408 0.057 (0.042, 0.075) 1.99 Liu et al.,2024 1019 1155 0.085 (0.065, 0.000) 2.00 Overall (h² = 99.700%, p = 0.00)	Su et al.,2016	304	934	0.325 (0.295, 0.357)	1.99
Zhang et al.,2017 118 3780 0.031 (0.026, 0.037) 2.01 Hu et al.,2018 174 1760 0.099 (0.085, 0.114) 2.00 Deng et al.,2018 518 1961 0.0264 (0.245, 0.284) 2.00 Zhang et al.,2019 78 1903 0.041 (0.033, 0.051) 2.00 Sun et al.,2023 46 808 0.057 (0.042, 0.075) 1.99 Liu et al.,2024 64 1408 0.045 (0.035, 0.058) 2.00 Overall (I^2 = 99.700%, p = 0.000)	Ma et al.,2017	68	2508 🔶	0.027 (0.021, 0.034)	2.01
Hu et al.,2018 174 1760 0.099 (0.085, 0.114) 2.00 Deng et al.,2018 518 1961 ● 0.264 (0.245, 0.284) 2.00 Zhang et al.,2019 78 1903 ● 0.041 (0.033, 0.051) 2.00 Sun et al.,2023 46 808 ● 0.057 (0.042, 0.075) 1.99 Liu et al.,2024 64 1408 ● 0.045 (0.035, 0.058) 2.00 Zheng et al.,2024 1019 1155 ● 0.882 (0.862, 0.900) 2.00 Overall (h² = 99.700%, p = 0.000) ● ● 0.086 (0.063, 0.113) 100.	Zhang et al. 2017	118	3780	0.031 (0.026 0 0.37)	2.01
Deng et al.,2018 518 1961 ↓ 0.264 (0.245, 0.284) 2.00 Zhang et al.,2019 78 1903 ↓ 0.041 (0.033, 0.051) 2.00 Sun et al.,2023 46 808 ↓ 0.057 (0.042, 0.075) 1.99 Liu et al.,2024 64 1408 ↓ 0.045 (0.035, 0.058) 2.00 Zheng et al.,2024 1019 1155 ↓ ↓ 0.882 (0.862, 0.900) 2.00 Overall (I^2 = 99.700%, p = 0.000) ↓ ↓ ↓ 0.086 (0.063, 0.113) 100.	Hu et al. 2018	174	1760	0.099 (0.085, 0.114)	2.00
Zhang et al.,2019 78 1903 2.00 Sun et al.,2023 46 808 0.057 (0.042, 0.054) 2.00 Liu et al.,2024 64 1408 0.045 (0.035, 0.058) 2.00 Zheng et al.,2024 1019 1155 0.882 (0.862, 0.900) 2.00 Overall (h² = 99.700%, p = 0.000) ● 0.086 (0.063, 0.113) 100.	Deng et al. 2018	518	1961	0.264 (0.245, 0.284)	2.00
Line tal.,2023 46 808 0.057 (0.042, 0.075) 1.99 Line tal.,2024 64 1408 0.047 (0.055, 0.058) 2.00 Zheng et al.,2024 1019 1155 0.882 (0.862, 0.900) 2.00 Overall (I/2 = 99.700%, p = 0.000) ◆ 0.086 (0.063, 0.113) 100.	Zhang et al. 2010	78	1903	0.243, 0.244)	2.00
Current 1,2223 -0 000 -1.96 0.037 (0.042, 0.073) 1.96 Liu et al.,2024 64 1408 ● 1 0.045 (0.035, 0.058) 2.00 Zheng et al.,2024 1019 1155 ● ● 0.882 (0.862, 0.090) 2.00 Overall (I*2 = 99.700%, p = 0.000) ● ● 0.866 (0.063, 0.113) 100.	Sun et al. 2013	16	808	0.057 (0.035, 0.037)	1 99
Line cal.,2024 04 1400 ■1 0.049 (0.035, 0.058) 2.00 Zheng et al.,2024 1019 1155 ● ● 0.882 (0.862, 0.900) 2.00 Overall (I^2 = 99.700%, p = 0.000) ● ● 0.086 (0.063, 0.113) 100.	Liu of al. 2023	40 64		0.045 (0.042, 0.075)	2.00
Zireing et al.,2024 1019 1155 ↓ 0.882 (0.862, 0.900) 2.00 Overall (I^2 = 99.700%, p = 0.000) ↓ 0.086 (0.063, 0.113) 100.	Liu et al.,2024	1010			2.00
Overall $(r^2 - 99.700\%, p = 0.000)$ U.086 $(0.063, 0.113)$ 100.	Zitieng et al.,2024	1019			2.00
	Overall (1/2 = 99.700	u‰, p = 0.00	Ŷ	0.086 (0.063, 0.113)	100.00



risk subjects, a pooled prevalence of obstructive sleep apnoea (OSA) of 16.8% (95% CI: 12.7%-20.8%) was observed, which was significantly higher than the overall pooled prevalence of 11.8%.

Meta-Regression Analysis

Meta-regression analyses identified several covariates significantly associated with heterogeneity in OSA prevalence estimates (Table 4). The survey period demonstrated a positive temporal trend, with a 0.036-unit increase in prevalence per time unit (95% CI: 0.005–0.067; P=0.025). Sex-based differences were significant, showing a 0.062-unit reduction in prevalence among females compared to males (95% CI: -0.123–-0.001; P=0.047). Geographic variations (95% CI:



Figure 4 Sensitivity Analysis Restricting to High-Quality Studies.

0.002-0.534; P=0.035), Occupational factors (95% CI: 0.002-0.047; P = 0.047), sampling strategies (95% CI: -0.162-0.021; P=0.012), were identified as potential sources. Methodological rigor, as reflected by RoB scores, reduced prevalence estimates by 0.027 units per score increment (95% CI: -0.095--0.008; P =0.022). In contrast, region of study (P=0.336), age range (P=0.187), and sleep monitoring methods (P=0.874) exhibited no significant association with OSA prevalence heterogeneity.

Discussion

In recent years, studies on obstructive sleep apnea (OSA) conducted by Chinese researchers have been limited in number, and the findings show substantial variability attributable to a myriad of factors such as geographic differences, study design, and population characteristics. This systematic evaluation and meta-analysis aimed to elucidate the prevalence of obstructive sleep apnoea (OSA) and its associated influencing factors in China. By integrating data from multiple studies, we were able to gain a more comprehensive perspective and provide important baseline information for understanding this complex disease.

The findings suggest that the prevalence of OSA in China ranges from 1.2% to 88.2%, with an overall prevalence of 11.8%. This finding is consistent with the results of several international studies,^{6,75} which may be closely related to the effects of population aging, lifestyle changes and environmental factors in China. However, considerable heterogeneity was observed across studies due to differences in survey year, gender, and sampling method.^{76,77}

In accordance with the findings of the global literature, our study revealed a markedly elevated prevalence of obstructive sleep apnoea (OSA) in males compared to females (11.1% vs 6.0%). This disparity may be attributed to

			Effect	
dy	Events	Total	(95% Cl)	
et al., 2001	32	784	• • • • • • • • • • • • • • • • • • •	7, 0.055)
o et al.,2004	15	678	● 0.022 (0.01	1, 0.033)
∕e et al.,2005	136	1220	0.111 (0.09	4, 0.129)
i et al.,2005	2262	3648	• 0.620 (0.60	4, 0.636)
iang et al.,2006	20	1065	0.019 (0.01	1, 0.027)
i et al.,2006	57	153	0.373 (0.29	6, 0.449)
lu et al.,2007	131	6304	● 0.021 (0.01	7, 0.024)
iu et al.,2007	448	10531	0.043 (0.03	9, 0.046)
hang et al.,2008	17	767	● 0.022 (0.01	2, 0.033)
hang et al.,2010	149	1015	0.147 (0.12	5, 0.169)
i et al.,2010	310	6447	0.048 (0.04	3, 0.053)
<i>l</i> la et al.,2011	428	1004	0.426 (0.39	6, 0.457)
lin et al.,2012	94	865	0.109 (0.08	8, 0.129)
lu et al.,2013	158	4045	• 0.039 (0.03	3, 0.045)
hao et al.,2013	481	4988	0.096 (0.08	8, 0.105)
heng et al.,2013	42	335	↔ 0.125 (0.09	0, 0.161)
Sun et al.,2014	121	3085	0.039 (0.03	2, 0.046)
lu et al.,2014	349	6842	0.051 (0.04	6, 0.056)
iu et al.,2014	444	10819	0.041 (0.03	7, 0.045)
lg et al.,2015	33	819	• 0.040 (0.02	7, 0.054)
Vu et al.,2016	155	567	• 0.273 (0.23	7, 0.310)
Cao et al.,2018	32	200	0.165 (0.11	4, 0.216)
Zhang et al.,2018	286	1726	0.166 (0.14	8, 0.183)
Guo et al.,2023	1119	3650	• 0.307 (0.29	2, 0.322)
heng et al.,2024	1019	1155	• 0.882 (0.86	4, 0.901)
Overall, DL (l² = 99	.8%, p < 0.0	00)	0.168 (0.12	7, 0.208)

NOTE: Weights are from random-effects model

Figure 5 Forest plot of sensitivity analysis including only studies that assessed the prevalence of OSA through sleep studies in both high- and low-risk subjects.

the influence of male physiology and lifestyle habits, including but not limited to obesity, smoking, and hormonal imbalances.⁷⁸ Furthermore, age was found to have a significant impact on the prevalence of OSA, with the highest rates observed in individuals aged 65–85 years.⁷⁹ This finding indicates that as the population ages, the necessity for management and intervention for OSA will increase significantly, thereby underscoring the urgent need for the

Covariate	Meta-Regression Coefficient	95% CI	Р
Survey period	0.036	0.005 to 0.067	0.025
Sex	-0.062	-0.123 to -0.001	0.047
Region of Study	-0.114	-0.031 to 0.011	0.336
Geographic Area	0.268	0.002 to 0.534	0.035
Age Range	0.170	-0.041 to 0.207	0.187
Careers	0.254	0.002 to 0.047	0.047
Sleep monitoring methods	0.018	-0.071 to 0.084	0.874
RoB score	-0.027	-0.095 to -0.008	0.022
Sampling Strategy	-0.029	-0.162 to -0.021	0.012

development of more appropriate screening and treatment options for older adults. The results of the meta-analysis demonstrated a notable increase in the prevalence of OSA on an annual basis between 2000 and 2024, particularly during the period between 2021 and 2024, when it exhibited a significant rise to reach 26.9%. It is essential to recognize that the observed increase in prevalence may be partially attributed to advancements in public awareness of obstructive sleep apnoea (OSA) and improvements in diagnostic methodologies over the years. The Healthy China 2030 initiative, launched in 2010, placed a significant emphasis on sleep health, which, in turn, has led to a marked increase in both public and clinical awareness of sleep disorders, including OSA. This shift in awareness has likely facilitated more widespread screening and diagnosis, thereby contributing to the higher prevalence rates reported in recent years. The heightened recognition of sleep disorders has been bolstered by various public health campaigns and an increasing acknowledgment of the importance of sleep health within both the medical community and the general public. Additionally, it is crucial to consider the evolution of sleep medicine in China over the 24-year study period. The expansion of sleep medicine services, marked by a growing number of sleep disorder specialists and an increase in diagnostic facilities, has likely played a significant role in the rising identification of OSA cases.⁸⁰ As the capacity for diagnosing OSA has improved, the prevalence rates may reflect these enhancements in diagnostic infrastructure. However, granular data regarding the number of specialists and the expansion of diagnostic facilities were not available in the majority of the included studies, preventing us from directly adjusting for these potential confounding factors.

The present analysis also revealed a significant effect of geographic location on the prevalence of obstructive sleep apnoea (OSA), with higher prevalence rates observed in the northwestern and northeastern regions of China and relatively lower rates in the eastern and southwestern regions. This discrepancy may be closely associated with synergistic interactions between dietary habits, environmental, socioeconomic, and healthcare. The significantly elevated prevalence of obstructive sleep apnoea (OSA) in Northwest China (17.8%) and Northeast China (16.9%) can be partially attributed to region-specific dietary habits.⁸¹ These regions typically consume calorie-dense and meat-heavy foods, contributing to higher obesity rates. Given that obesity is a well-established risk factor for OSA due to fat deposition in the pharyngeal area, the increased prevalence of obstrutial hypertension rates. This correlation may partly explain the elevated OSA prevalence, as hypertension frequently coexists with sleep-disordered breathing.⁸¹ Geoclimatic extremes compound biological vulnerabilities. Additionally, particulate matter levels in industrial cities like Lanzhou (Northwest) and Shenyang(Northeast) far exceed WHO guidelines, and air pollution, inducing airway inflammation that worsens OSA severity.

Socioeconomic factors further complicate these dynamics. Northwest China's polysomnography availability lower, compounded diagnostic delays in communities. Northeast China's aging industrial workforce faces higher occupational OSA risks, yet routine health screenings rarely address sleep-related issues. These systemic gaps contrast sharply with coastal regions like East China, where better income levels and specialist availability facilitate earlier intervention.

Our analysis indicated that drivers exhibit a significantly higher prevalence of OSA (15.3%, 95% CI: 11.3–19.8%) compared to other occupational groups such as civil servants (7.3%) and clerks (7.2%). This finding is consistent with previous studies that have highlighted the increased risk of OSA in drivers due to prolonged sitting, fragmented sleep due to shift work, and exposure to traffic-related stressors.^{82,83} It is critical to recognize that while we can attribute higher rates of OSA prevalence among drivers to their occupational environment and lifestyle, other demographic and health-related confounders must also be considered. For example, the prevalence of obesity in occupational populations can vary significantly. Future research should aim to control for these confounding factors more rigorously. Stratifying analyses by body mass index (BMI), sleep habits, and comorbid conditions such as hypertension and diabetes can help isolate the true effect of occupational exposure on OSA prevalence.

The pronounced prevalence of OSA in low-quality studies compared to high-quality studies suggests that methodological deficiencies may inflate estimates. Frequently, these studies lack standardized diagnostic criteria, appropriate sampling methods, or adequate sample sizes, which could consequently lead to either over-diagnosis or misdiagnosis of OSA. Several low-quality studies utilized convenience sampling or targeted specific populations, which can lead to selection bias. High-quality studies, on the other hand, employed stratified sampling methods that enhance representativeness across geographic and demographic spectra. This methodological rigor is reflected in their comparatively lower prevalence estimates, which likely provide a more accurate picture of OSA distribution across China. In conclusion, the quality disparities across the included studies are likely to result in biased prevalence estimates, demonstrating the necessity for methodological standardization in future research to ensure accurate depiction of OSA prevalence and epidemiology. Furthermore, the combined prevalence of laboratory and portable monitoring modalities was found to be similar, indicating that the prevalence of obstructive sleep apnoea (OSA) remains consistent across monitoring settings.⁸⁴ Despite the absence of significant differences between monitoring modalities, portable testing has been subject to criticism for underdiagnosing cases of mild OSA.⁸⁵ It is therefore recommended that future studies investigate the potential impact of different monitoring modalities on outcomes in order to improve the detection rates and diagnostic accuracy of OSA. The extreme prevalence estimates in three studies highlight critical methodological challenges. Zheng et al's⁷⁴ 88.2% prevalence—the highest reported—likely reflects their exclusive focus on snoring patients identified through respiratory clinics, violating basic epidemiological sampling principles. Similarly, Li et al's²⁰ otolaryngology clinic-based recruitment and Ma et al's⁶⁹ non-standard diagnostic thresholds exemplify how sampling frame and measurement variability can distort burden estimates. While these studies met our inclusion criteria, their design limitations reduce comparability with population-based investigations. Their exclusion in sensitivity analyses produced a more conservative estimate (7.8%) that better reflects general population risk.

Our stratified analyses revealed that sampling methodology significantly influenced prevalence estimates. Studies employing two-step designs (screening both high- and low-risk populations) higher OSA prevalence than single-step designs (13.6% vs 7.4\%, p<0.001). This discrepancy is a result of single-step studies not testing low-risk subjects due to funding or resource constraints thereby underestimating undiagnosed cases in the general population. These findings align with global meta-analyses demonstrating that selective sampling of high-risk cohorts underestimates OSA prevalence.⁶ Standardizing risk-stratified sampling frameworks is thus critical for future epidemiological studies.

Given the identified methodological disparities among studies, there is a clear necessity for standardization in future research to ensure more accurate prevalence estimates. We recommend that subsequent studies prioritize larger, multicenter cohorts utilizing harmonized diagnostic protocols and geographically stratified sampling frameworks, as such approaches are vital for enhancing public health strategies and effectively addressing the increasing burden of OSA.

Limitations

While this multilevel meta-analysis provides valuable insights into the prevalence of obstructive sleep apnea (OSA) across China, several methodological constraints must be carefully considered. The high heterogeneity observed in our analysis (I^2 =99.7%) can be attributed to a variety of factors, including differences in sample selection, geographic diversity, and the range of diagnostic and measurement tools employed. This significant heterogeneity introduces uncertainty in our overall prevalence estimates and complicates the comparability of results across studies.

Firstly, although our study encompassed 178,049 participants from a broad range of geographic regions, the uneven distribution of studies introduces potential selection bias. Most studies were focused on urban populations in the developed eastern provinces, while only two studies specifically targeted rural populations in Northwest and Southwest China—regions that are undergoing rapid dietary and lifestyle changes, which could have a disproportionate impact on OSA risk. This urban-rural imbalance, coupled with the underrepresentation of 11 provincial-level administrative divisions, limits the generalizability of our geographic stratification results and may obscure emerging epidemiological trends in China's rapidly developing interior regions. We emphasize the need for more research in rural regions to obtain a more accurate national prevalence estimate.

Additionally, variations in diagnostic criteria and methodologies across studies further complicate the interpretation and comparison of prevalence rates among different populations. While our age-stratified analysis captured developmental trends, the differential AHI thresholds between pediatric and adult OSA diagnoses may introduce measurement variability. Future studies employing age-specific diagnostic criteria across the lifespan could enhance precision. The increase in the prevalence rate over the years may reflect both changes: on the one hand, it may be that the actual number of people with the disease is indeed increasing, and on the other hand, it may be that the increase in the detection rate has been brought about by the spread of diagnostic technology over the years. This interdependence may confound relevant epidemiological trends.

Given the considerable heterogeneity, we advise caution in interpreting our findings across various subgroups, such as age, gender, and geographic region. The limitations outlined above may influence the implications of our study for

policy-making and intervention strategies targeting high-risk groups. We recommend that future research adopt more standardized methodologies and consistent diagnostic criteria to enhance the comparability and reliability of epidemio-logical data across diverse populations.

Conclusions

This systematic evaluation and meta-analysis revealed the prevalence of obstructive sleep apnoea (OSA) and its associated influencing factors in China. The findings indicated that the overall prevalence of OSA was 11.8%, a figure that may be conservative and is likely to increase in the coming decades as the median age and prevalence of obesity rise. The present study demonstrates that the prevalence of obstructive sleep apnoea (OSA) exhibits significant gender and age-related differences. In particular, the data indicate that men have a significantly higher prevalence of OSA than women, with the highest prevalence observed in older age groups (65–85 years). Geographic location, lifestyle factors, and occupational exposures significantly influence OSA prevalence, particularly in the northwestern and northeastern regions of China. The prevalence among high-risk occupations, especially drivers, is markedly elevated. These findings underscore the urgency of integrating OSA screening into routine health assessments for high-risk groups (eg, male drivers, aging populations) and prioritizing resource allocation to Northwest China, where dietary transitions and hypertension epidemics exacerbate OSA burden.

Additionally, the rising OSA burden parallels the rapid advancements in sleep medicine infrastructure in China since 2000; however, disparities persist, particularly in rural and low-income areas. Strengthening specialist training programs and equitable resource distribution remains critical to mitigating diagnostic delays. Policymakers should advocate for standardized diagnostic protocols and rural healthcare capacity-building to address underrepresentation in current studies.

OSA is not only prevalent in China, but is also associated with impaired quality of life, reduced productivity, increased traffic accidents and an increased risk of cardiovascular and metabolic diseases. Future research should focus on longitudinal designs to explore causal pathways linking urbanization and obesity to OSA. There is also a need for cost-effectiveness analyses of targeted screening programs to better understand their impact on population health. By enhancing public awareness and education regarding OSA, we can lay the groundwork for comprehensive public health strategies to mitigate this significant health issue in China.

Data Sharing Statement

The original contributions presented in the study are included in the article files, further inquiries can be directed to the corresponding author.

Ethical Approval Statement

This study was a secondary analysis based on published literature and did not involve the direct participation of human subjects and therefore did not require ethics committee approval. All included studies declared compliance with ethical norms in their original publications.

Author Contributions

YQ N: Conceptualization, Methodology, Investigation, Data Curation, Formal Analysis, Writing - Original Draft.

SW S: Methodology, Validation, Investigation, Data Curation, Formal Analysis, Visualization, Writing - Review & Editing.

YL W: Software, Validation, Formal Analysis, Resources, Writing - Review & Editing.

LL C: Conceptualization, Methodology, Supervision, Writing - Review & Editing.

YF S: Conceptualization, Methodology, Supervision, Writing - Review & Editing.

XC Z: Supervision, Validation, Funding acquisition, Project Administration, Writing - Review & Editing.

All authors have approved the final version of the manuscript for publication, agreed to submit this work to the current journal, and accept full accountability for all aspects of the research.

Funding

This work was supported by Funds for the Department of Education of Liaoning Province (LJ112410159016), China.

Disclosure

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

- 1. Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2021;144(3):e56–e67. doi:10.1161/CIR.00000000000988
- Evans EC, Sulyman O, Froymovich O. The goals of treating obstructive sleep apnea. Otolaryngol Clin N Am. 2020;53(3):319–328. doi:10.1016/j. otc.2020.02.009
- 3. Léger D, Stepnowsky C. The economic and societal burden of excessive daytime sleepiness in patients with obstructive sleep apnea. *Sleep Med. Rev.* 2020;51:101275. doi:10.1016/j.smrv.2020.101275
- 4. Benjafield AV, Ayas NT, Eastwood PR, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. *Lancet Respir Med.* 2019;7(8):687–698. doi:10.1016/S2213-2600(19)30198-5
- 5. Senaratna CV, Perret JL, Lodge CJ, et al. Prevalence of obstructive sleep apnea in the general population: a systematic review. *Sleep Med. Rev.* 2017;34:70–81. doi:10.1016/j.smrv.2016.07.002
- Suri TM, Ghosh T, Mittal S, Hadda V, Madan K, Mohan A. Systematic review and meta-analysis of the prevalence of obstructive sleep apnea in Indian adults. Sleep Med. Rev. 2023;71:101829. doi:10.1016/j.smrv.2023.101829
- 7. Waters KA, Suresh S, Nixon GM. Sleep disorders in children. Med J Aust. 2013;199(8):S31-35. doi:10.5694/mja13.10621
- 8. Marcus CL, Brooks LJ, Draper KA, et al. Diagnosis and management of childhood obstructive sleep apnea syndrome. *Pediatrics*. 2012;130(3): e714–755. doi:10.1542/peds.2012-1672
- 9. Su X, Liu L, Zhong L. Prevalence of obstructive sleep ap nea syndrome in China: a meta analysis. Chin J Evid Based Med. 2021;21 (10):1187–1194.
- 10. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372: n71.
- Munn Z, Moola S, Riitano D, Lisy K. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Health Policy Manag. 2014;3(3):123–128. doi:10.15171/ijhpm.2014.71
- 12. Rostom A, Dubé C, Cranney A, et al. Celiac disease: summary. AHRQ evidence report summaries2004(104):1-6.
- 13. Ip MS, Lam B, Lauder IJ, et al. A community study of sleep-disordered breathing in middle-aged Chinese men in Hong Kong. *Chest*. 2001;119 (1):62–69. doi:10.1378/chest.119.1.62
- 14. Lin S, Zhao X, Li S. Epidemiological investigation of snoring and sleep apnea syndrome in urban and suburban residents. *Weifang Med Coll*. 2002;24(3):185–187.
- 15. Huang S, Li Q, Zazhi Zjhh. Prevalence of obstructive sleep apnea-hypopnea syndrome in Chinese adults aged over 30 yr in Shanghai. Chin J Tuberc Respir Dis. 2003;26(5):268–272.
- Zhang Q, He Q, Du Q, et al. Epidemiologic study on sleep apnea-hypopnea syndrome by home investigation in Chengde city. *Chinese Journal of Tuberculosis Respiratory Diseases*. 2003;26(5):273–275.
- 17. Ip MS, Lam B, Tang LC, Lauder IJ, Ip TY, Lam WK. A community study of sleep-disordered breathing in middle-aged Chinese women in Hong Kong: prevalence and gender differences. *Chest.* 2004;125(1):127–134. doi:10.1378/chest.125.1.127
- Bei W, Jingcai X, Changxu H, Chonggang W. Epidemiological studies of sleep apnea-hypopnea syndrome: a questionnaire survey of Taiyuan. *Chin J Tuberc Respir Dis.* 2004;27(11):760–762.
- Ye J, Wang X, Han D, Gao L. Epidemic survey of the middle and aged women related obstructive sleep apnea hypopnea syndrome in Beijing. *Chin J Otorhinolaryngol Head Neck Surg.* 2005;40(8):611–617.
- Li M, Wang Y, Hua S, et al. The prevalence of obstructive sleep apnea-hypopnea syndrome in adults aged over 20 years in Changchun city. *Chin J Tuberc Respir Dis.* 2005;28(12):833–835.
- 21. Gumi L, Ning S, Weihua F, Li G. Epidemiological investigation of sleep apnoea and hypoventilation syndrome in flight crew. *Chin J Aerosp Med.* 2006;17(2):139–142.
- 22. Dongqing H, Xiangfu W, Huihong Y, Zhaoxia L. Clinical epidemiological investigation of obstructive sleep apnoea hypoventilation syndrome and analysis of related factors. *Med Clin Res.* 2006;23(3):297–299.
- 23. Qinghai L, Han C. Investigation and analysis of sleep apnoea in 57 cases of retired cadres. J Nav Med. 2006;27(3):230-231.
- 24. Yiduo H, Yudan H. Analysis of the incidence of obstructive sleep apnoea hypoventilation syndrome in FAW workers. *Chin Community Physician*. 2008;10(6):33.
- 25. Jianhong L, Caizhou W, Luying H. Epidemiological survey on snoring and obstructive sleep apnoea hypoventilation syndrome in Guangxi. *Chin J Epidemiol*. 2007;28(2):115–118.
- 26. Yan G, Xuezhang G. Survey on the prevalence of obstructive sleep apnoea hypoventilation syndrome in patients aged 30 years or above attending the clinic and intervention in Luwan district. *J Clin Pulmonol.* 2007(11):1171–1173.
- 27. Zou X, Zhu S, Li D. Investigation on prevalence of OSAHS in adults aged over 20 years in Shaoyang. China J Modern Med. 2007;17:956–959.
- 28. Weige J, Qing Z, Quanying H, Zhili X. Prevalence of obstructive sleep apnoea and hypoventilation among drivers. *Chin J Tuberc Respir Med.* 2008;31(9):656–658.
- 29. Weiwei Z. Investigation and research on the prevalence of habitual snoring and obstructive sleep apnoea hypoventilation syndrome in children. Shandong University; 2008.

- Saiyu H, Songjie X, Liyan N, Jinjian G, Gayun H, Bei CB. Prevalence of obstructive sleep apnoea and hypoventilation syndrome in the health check-up population in Wenzhou. *Chin J Prev Med.* 2009;10(11):1013–1015.
- Qichang L, Jianchai HUANG, Haibo D, Hongbo H. Epidemiological survey of obstructive sleep apnoea and hypoventilation syndrome in people over 20 years old in Fuzhou City. *Chin J Tuberc Respir Med.* 2009;32(3):193–197.
- 32. Ruifeng G, Wenjun L, Xubin M, Yiping W. Correlation analysis of the prevalence of obstructive sleep apnoea and hypoventilation syndrome in Qingdao. *Chin J Otolaryngol Skull Base Surg.* 2009(4):272–275.
- Yunyun G, Xiuhua Z, Haihuan Z, Fucai S. Preliminary analysis of factors associated with obstructive sleep apnoea and hypoventilation syndrome. *China Med J.* 2010(2):54–56.
- 34. Guoqiang M, Guoyi D, Jiping L, Xinguang Z. Epidemiological survey of obstructive sleep apnoea and hypoventilation syndrome in pastoralists over 20 years old in Dongwuqi, Inner Mongolia. *Chin J Clin Physicians*. 2010(7):1070–1073.
- 35. Yanhui Z. Epidemiological Survey of OSAHS Among Taxi Drivers in Hohhot, Inner Mongolia [Dissertation]. Inner Mongolia Medical University; 2010.
- 36. Qichang L, Jianchai H, Haibo D, Gongping C. Epidemiological survey of obstructive sleep apnoea and hypoventilation syndrome in the elderly in Fuzhou City. *Chinese J Geriatrics*. 2010(4):332–335.
- 37. Li AM, So HK, Au CT, et al. Epidemiology of obstructive sleep apnoea syndrome in Chinese children: a two-phase community study. *Thorax*. 2010;65(11):991–997. doi:10.1136/thx.2010.134858
- 38. Wei W. Prevalence and risk factors of obstructive sleep apnea syndrome In 3-14 yearsold children in Beijing: a cross-sectional surveyabstract. *Sleep*. 2020;43:A346. doi:10.1093/sleep/zsaa056.906
- 39. Yanning M, Xiaoqin W, Pingping B. Epidemiological study of sleep apnoea syndrome in Taiyuan. China Med Guide. 2011;9(30):108-110.
- 40. Xiaowen C, Weihua X, Huiwei F, Yunling J. Investigation of obstructive sleep apnoea hypoventilation syndrome. Med Inf. 2011;24(13):4125-4126.
- 41. Wei J, Min H, Yiming H, Nuo S, Caihong L, Honglie C. A community-based survey study of sleep apnoea syndrome in Women in Liwan District. *Front med.* 2012(33):53–54.
- 42. Yunping X, Jianjun H, Caijun C, Zhibin Z. Analysis of risk factors for obstructive sleep apnoea hypoventilation syndrome in male basic rank officers and soldiers. *Int J Otolaryngol*. 2020;26(5):559–564.
- 43. Hu Q, Yang Y, Zhou H. Epidemiological study on children with obstructive sleep apnea hypopnea syndrome aged from 4 to 7 years in Putuo District of Shanghai. *Chin J Ophthalmol Otorhinolaryngol.* 2014;14:316–319.
- 44. Jingna W. Epidemiological investigation of moderate-to-severe snoring and obstructive sleep apnoea hypoventilation syndrome in hit-and-run drivers [dissertation]. Chengde Medical College; 2013.
- 45. Yang Z, Jianrui L, Liwei W, et al. Epidemiological survey of snoring and obstructive sleep apnoea hypoventilation syndrome among adults in Chaoyang District, Beijing. *China Med J.* 2013;10(27):108–111.
- 46. Zheng T, Zhang L, Tian G-Y, Yu Q-L, Liao R-H, Liang L-N. An epidemiological survey of snoring disease and OSAHS among 374 truck drivers in Guangzhou, China. *Chin J Ind Hyg Occup Dis*. 2013;31(6):422–424.
- 47. Xia S. Epidemiological Survey of Obstructive Sleep Apnoea Hypoventilation Syndrome Among University Staff in Kunming and Analysis of Related Factors. Kunming Medical University; 2014.
- 48. Hu Q, Du C, Yang Y, Bai S. Prevalence of obstructive sleep apnea-hypopnea syndrome in Chinese adults aged over 20 years in Putuo district of Shanghai. Chin J Ophthalmol. 2017;17(1):49–54.
- Rongchun P, Min H, Shiqing R. Analysis of prevalence survey of obstructive sleep apnoea hypoventilation syndrome in preschool children in Liwan District, Guangzhou City. Chin J Child Health. 2014;22(1):68–70.
- 50. Yujie C, Linglin Y, Guiying D, Xiaobing W. Epidemiological survey of obstructive sleep apnoea hypoventilation syndrome in Sichuan provincial organ units. Proceedings of the 2014 National Sleep Apnoea Academic Annual Conference. 2014.
- 51. Liu J, Wei C, Huang L, et al. Prevalence of signs and symptoms suggestive of obstructive sleep apnea syndrome in Guangxi, China. *Sleep Breathing*. 2014;18:375–382. doi:10.1007/s11325-013-0896-2
- 52. XiaoGuang W, XiaoGuang H. Epidemiological survey of OSAHS between the Han and Hani Nationalities in Yunnan Province. J Kunming Med Univ. 2014;35(11).
- 53. Ng SS, Chan T-O, To K-W, et al. Prevalence of obstructive sleep apnea syndrome and CPAP adherence in the elderly Chinese population. PLoS One. 2015;10(3):e0119829. doi:10.1371/journal.pone.0119829
- 54. Dan W, Hong Y, Cheng Z, Xianwei Y. Epidemiological investigation of obstructive sleep apnoea hypoventilation syndrome in 567 drivers in Guiyang City. *Med Inf.* 2016;29(32):30–32.
- 55. Xiuhong J, Qiang D, Jingjing Z, Xiaoyin S. Investigation and analysis of obstructive sleep apnoea hypoventilation syndrome in grassroots civil servants. *Chinese Med J*. 2016;51(8):95–98.
- 56. Qian W, Hui Z, Qiuxia C, Jiangmin H. Analysis of the prevalence of sleep apnoea hypoventilation syndrome and related risk factors among taxi drivers in a city. J Emerg Crit Care Med. 2016(1):60–61.
- 57. Ying L, Chunlin T, Wenfei Y, Yanfang Y, Wang Z, Hu JR. Prevalence of obstructive sleep apnoea hypoventilation syndrome in professional drivers and its relationship with traffic accidents. *Chinese Med J.* 2016;96(48):3902–3905. doi:10.3760/cma.j.issn.0376-2491.2016.48.011
- 58. Su Y, Xu W, Wang X, et al. Prevalence of obstructive sleep apnea-hypopnea syndrome in adults aged over 60 yeaes in dongying city. J Clin Otolaryngol Head Neck Surg. 2016;30(4):299–305.
- 59. Hengjie M, Jingbo W, Jing Z, Chunke Z. Study on the epidemiological survey of sleep apnoea syndrome in the population of Penglai City. *China Health Industry*. 2017;14(21):1–2.
- 60. Ting Z. Epidemiological survey of obstructive sleep apnoea hypoventilation syndrome in people over 30 years of age in Nantong City. Proceedings of the 2017 International Orthodontic Congress and the 16th National Orthodontic Symposium. 2017.
- 61. Weijuan H. Epidemiological survey of OSAHS among people over 20 years old in Haiyuan County. Ningxia Medical University. 2017.
- 62. Pingping D, Dong L, Xiaoyi W, Demin H. Epidemiological investigation of snoring and obstructive sleep apnoea hypoventilation syndrome in adult females in Dongbao District, Jingmen City by Epworth Sleepiness Scale combined with micromotion-sensitive mattress-based sleep monitoring system. *China Medical Digest*. 2018;33(03):217–222.

- 63. Wenguang C, Xiaoling L, Yongli M, Jing B. Survey on the prevalence of sleep apnoea hypoventilation syndrome among officers and soldiers of a detachment of the armed police force of inner mongolia general brigade residing in Hohhot City. World Digest Latest Med Information. 2018 (89):193–194.
- 64. Qi Z, Kan Z, Zhihong X. Epidemiological survey of obstructive sleep apnoea hypoventilation syndrome in a community in Taiyuan City. *Clin Med Practice*. 2019;28(6):409–413.
- 65. Xiaoping Z, Dengquan Y, Xiaoming H, Shaoxin W. Survey on the prevalence and quality of life of obstructive sleep apnoea hypoventilation syndrome in children aged 6-12 years in Yibin City. Anhui Medicine. 2019;40(05):585–589.
- 66. Yunping X, Jianping H, Caijun C, Jianfeng Y. Analysis of risk factors for obstructive sleep apnoea hypoventilation syndrome in male soldiers. *Chinese Journal of Otolaryngology and Skull Base Surgery*. 2020;26(5):559–564.
- Peichuan H, Qiong O, Minxia P, Baixin C. Awareness of the dangers of snoring and prevalence of obstructive sleep apnoea among civil servants. Chin J Tuberc Respir Med. 2020;43(7):553–556.
- 68. Jinli Y. Clinical epidemiological investigation and related factors of obstructive sleep apnoea hypoventilation syndrome. J Armed Police Logistics Coll. 2021;30(06):26–29.
- 69. Ying MA, Baohong G, Shenghong Z. Prevalence and awareness of 658 cases of obstructive sleep apnoea hypoventilation syndrome in high-risk groups. *Anhui Medicine*. 2022;26(12):2456–2459.
- 70. Juan L, Junyi L, Mingqiu L, Feng L. Survey on the prevalence of obstructive sleep apnoea hypopnoea syndrome in drivers of online car rental vehicles and its relationship with traffic accidents. *China Otorhinolaryngol Head Neck Surg.* 2022;29(1):20.
- Fuqin S, Feifan L, Shaorui B, Xueru R. Epidemiological survey of obstructive sleep apnoea hypoventilation syndrome in people over 20 years old in Wuhu City. *China Sci Tech J Database Med.* 2019(08):00264–00265.
- 72. Pei G, Ou Q, Shan G, et al. Screening practices for obstructive sleep apnea in healthy community people: a Chinese community-based study. *J Thoracic Dis*. 2023;15(9):5134. doi:10.21037/jtd-22-1538
- 73. Sisi L, Hongying X, Qing X, Qiuping S, Rui Z. Survey on the prevalence and quality of life of preschool children with obstructive sleep apnea. *Chin Sci Tech J Database Med Health.* 2024(8):0099–0102.
- 74. Tong Z, Kan Y, Yifeng Q, Hongxia S, Xiaofeng L, Wenwen Y. Analysis of risk factors for obstructive sleep apnoea in adult snorers. J Oral Maxillofac Surg. 2024;22(2):137.
- 75. de Araujo Dantas AB, Gonçalves FM, Martins AA, et al. Worldwide prevalence and associated risk factors of obstructive sleep apnea: a meta-analysis and meta-regression. *Schlaf & Atmung*. 2023;27(6):2083–2109. doi:10.1007/s11325-023-02810-7
- 76. Fuentes-López E, Rodríguez LJRmd C, Santín Martínez J, Fuentes-López E, Leiva Rodríguez I, Valdivia Cabrera G. Prevalence of obstructive sleep apnea syndrome in Chilean adults. A sub-study of the national health survey. *Revista Med de Chile*. 2020;148(7):895–905. doi:10.4067/S0034-98872020000700895
- 77. Horne RSC, Ong C, Weichard A, Nixon GM, Davey MJ. Are there gender differences in the severity and consequences of sleep disordered in children? Sleep Med. 2020;67:147–155. doi:10.1016/j.sleep.2019.11.1249
- 78. Geer JH, Hilbert J. Gender issues in obstructive sleep apnea. Yale J Biol Med. 2021;94(3):487–496. doi:10.1164/rccm.2109080
- 79. Fietze I, Laharnar N, Obst A, et al. Prevalence and association analysis of obstructive sleep apnea with gender and age differences Results of SHIP-Trend. J Sleep Res. 2019;28(5):e12770. doi:10.1111/jsr.12770
- 80. Samuel M, Park RY, Eastwood SV, et al. Trends in weight gain recorded in English primary care before and during the Coronavirus-19 pandemic: an observational cohort study using the OpenSAFELY platform. PLoS Med. 2024;21(6):e1004398. doi:10.1371/journal.pmed.1004398
- Wilborn C, Beckham J, Campbell B, et al. Obesity: prevalence, theories, medical consequences, management, and research directions. J Int Soc Sports Nutr. 2005;2(2):4–31. doi:10.1186/1550-2783-2-2-4
- Tregear S, Reston J, Schoelles K, Phillips B. Obstructive sleep apnea and risk of motor vehicle crash: systematic review and meta-analysis. J Clin Sleep Med. 2009;5(6):573–581. doi:10.5664/jcsm.27662
- Udholm N, Rex CE, Fuglsang M, Lundbye-Christensen S, Bille J, Udholm S. Obstructive sleep apnea and road traffic accidents: a Danish nationwide cohort study. Sleep Med. 2022;96:64–69. doi:10.1016/j.sleep.2022.04.003
- 84. Withers A, Maul J, Rosenheim E, O'Donnell A, Wilson A, Stick S. Comparison of home ambulatory type 2 polysomnography with a portable monitoring device and in-laboratory type 1 polysomnography for the diagnosis of obstructive sleep apnea in children. J Clin Sleep Med. 2022;18 (2):393–402. doi:10.5664/jcsm.9576
- Zeidler MR, Santiago V, Dzierzewski JM, Mitchell MN, Santiago S, Martin JL. Predictors of obstructive sleep apnea on polysomnography after a technically inadequate or normal home sleep test. J Clin Sleep Med. 2015;11(11):1313–1318. doi:10.5664/jcsm.5194

Nature and Science of Sleep



Publish your work in this journal

Nature and Science of Sleep is an international, peer-reviewed, open access journal covering all aspects of sleep science and sleep medicine, including the neurophysiology and functions of sleep, the genetics of sleep, sleep and society, biological rhythms, dreaming, sleep disorders and therapy, and strategies to optimize healthy sleep. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/nature-and-science-of-sleep-journal

🖪 🗙 in 🗖

903